lipid nanoparticles

Lipid nanoparticles with specific lipid compositions enable efficient delivery of nucleic acids to hematopoietic stem cells and immune cells, addressing the need for targeted gene editing and immune enhancement.

KR1020260163451APending Publication Date: 2026-11-16GENZYME CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020267033021
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-08
Filing Date
2025-03-07
Publication Date
2026-11-16

AI Technical Summary

Technical Problem

There is a need for a safe and effective in vivo method for targeted expression of polypeptides that enhance immune cell function in immune cells and targeted gene editing in hematopoietic stem cells.

Method used

Lipid nanoparticles comprising an ionizable lipid, a structural lipid, an auxiliary lipid, a PEG lipid, and a cell targeting group are used for targeted delivery of nucleic acids to hematopoietic stem cells and immune cells, with specific compositions and formulations to enhance delivery efficiency.

Benefits of technology

The lipid nanoparticles achieve high-efficiency transfection of immune cells and hematopoietic stem cells, with proteins encoded by nucleic acids detected in a significant percentage of cells and enhanced immune cell function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCT00030_ABST
    Figure PCT00030_ABST
Patent Text Reader

Abstract

Lipid nanoparticles, a composition, and methods for the preparation and use thereof are provided. The lipid nanoparticles contain an ionizable lipid, a structural lipid, a PEG lipid, and a specific amount of an auxiliary lipid. The lipid nanoparticles may further contain a cell targeting group coupled to the PEG lipid. The lipid nanoparticles may carry a cargo, for example, mRNA. The lipid nanoparticles may be used for the transfection of cells, for example, immune cells or hematopoietic stem cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present disclosure provides lipid nanoparticles for delivering nucleic acids to hematopoietic stem cells and immune cells, and methods for manufacturing and using the same. Background Technology

[0002] A safe and effective in vivo method is needed for the targeted expression of polypeptides that enhance immune cell function in immune cells and for targeted gene editing in hematopoietic stem cells (HSCs).

[0003] Lipid nanoparticles for targeted delivery of nucleic acids into target cells are provided, said lipid nanoparticles comprising an ionizable lipid, a structural lipid, an auxiliary lipid, a PEG lipid, and a cell targeting group, wherein said auxiliary lipid is present in a range of about 16 mol% to about 40 mol%.

[0004] In some aspects, the ionizable lipid comprises the structure of Formula I or a salt thereof:

[0005] [Chemical Formula I]

[0006]

[0007] (Here,

[0008] R 1 , R 2 , and R 3 Each is independently combined or C 1-3 It is an alkylene;

[0009] R 1A , R 2A , and R 3A are each independently combined or C 1-10 It is an alkylene;

[0010] R 1A1 , R 1A2 , R 1A3 , R 2A1 , R 2A2 , R 2A3 , R 3A1 , R 3A2 , and R 3A3 H and C are independently1-20 Alkyl, C 1-20 Alkenyl, -(CH2) 0-10 C(O)OR a1 , or -(CH2) 0-10 OC(O)R a2 And;

[0011] R a1 and R a2 C each independently 1-20 alkyl or C 1-20 It is alkenyl; R 3B Is

[0012]

[0013] And,

[0014] R 3B1 C 1-6 It is an alkylene;

[0015] R 3B2 and R 3B3 Each independently H or C 1-6 It is an alkyl).

[0016] In some aspects, the ionizable lipid comprises the structure of Formula II (Lipid 15):

[0017] [Chemical Formula II]

[0018] .

[0019] In some aspects, the ionizable lipid comprises the structure of formula III (KC2):

[0020] [Chemical Formula III]

[0021] .

[0022] In some aspects, the ionizable lipid comprises the structure of formula IV (KC3):

[0023] [Chemical Formula IV]

[0024] .

[0025] In some aspects, the ionizable lipid comprises the structure of formula V:

[0026] [Chemical Formula V]

[0027]

[0028] (Here, R 1 and R 2 Each is independently a lipid).

[0029] In some aspects, the ionizable lipid comprises the structure of formula VI:

[0030] [Chemical Formula VI]

[0031]

[0032] (Here, R 1 and R 2 Each is independently a lipid).

[0033] In some embodiments, where the ionizable lipid comprises the structure of Formula V or Formula VI, R 1 and R 2 Each is independently a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkenyl. In some embodiments, where the ionizable lipid comprises the structure of Formula V or Formula VI, R 1 and R 2 is the same lipid. In some embodiments, where the ionizable lipid comprises the structure of Formula V or Formula VI, R 1 and R 2 is a different lipid. In some embodiments, the lipid is a hydrocarbon (e.g., substituted or unsubstituted, saturated or unsaturated, branched or unbranched hydrocarbon). The hydrocarbon may be an alkane, an alkene, or an alkyne. In some embodiments, the hydrocarbon chain is saturated or unsaturated. In certain embodiments, the unsaturated hydrocarbon chain comprises at least one, at least two, at least three, at least four, at least five, or at least six carbon-carbon double bonds (e.g., cis double bonds and / or trans double bonds). In some embodiments, the lipid is a substituted or unsubstituted C 7-36It is an alkyl. In certain embodiments, the lipid is a substituted or unsubstituted C 7-36 It is an alkenyl. In certain embodiments, the lipid is an unsubstituted C 7-36 Alkyl or unsubstituted C 7-36 It is an alkenyl. In certain embodiments, the hydrocarbon is substituted with alkyl, alkenyl, alkynyl, amino, alkylamino, dialkylamino, trialkylamino, hydroxyl, alkoxy, carbonyl, halogen, aryl, heterocyclic, aromatic heterocyclic, cyano, amide, carbamoyl, carboxylic acid, ester, thioether, alkylthioether, thiol, ureido, or a combination thereof. Each of these groups may be substituted again. In some embodiments, the hydrocarbon is substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, or more than 10 substituents.

[0034] In some aspects, the lipid nanoparticles further include cargo.

[0035] In some aspects, the auxiliary lipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and sphingomyelin.

[0036] In some aspects, the auxiliary lipid is DSPC.

[0037] In some aspects, the structural lipid is selected from the group consisting of cholesterol, pecosterol, β-sitosterol, ergosterol, campesterol, stigmasterol, stigmasterol, and brassicasterol.

[0038] In some aspects, the PEG lipid is selected from the group consisting of distearoylglycerol-PEG (DSG-PEG), distearoyl-phosphatidylethanolamine-PEG (DSPE-PEG), dimyristoyl-phosphatidylethanolamine-PEG (DMPE-PEG), distearoyl-glycero-phosphoglycerol-PEG (DSPG-PEG), dimyristoyl-glycerol-PEG (DMG-PEG), dipalmitoyl-phosphatidylethanolamine-PEG (DPPE-PEG), dipalmitoyl-glycerol-PEG (DPG-PEG), and ceramide-PEG.

[0039] In some aspects, the ionizable lipid is present in a range of about 30 mol% to about 70 mol%.

[0040] In some aspects, the ionizable lipid is present in a range of about 40 mol% to about 60 mol%.

[0041] In some aspects, the ionizable lipid is present in a range of about 48 mol% to about 50 mol%.

[0042] In some aspects, the structural lipids are present in a range of about 20 mol% to about 50 mol%.

[0043] In some aspects, the above structural lipids are present in a range of about 30 mol% to about 40 mol%.

[0044] In some aspects, the above-mentioned structural lipid is cholesterol.

[0045] In some aspects, cholesterol is present in the range of about 25 mol% to about 40 mol%.

[0046] In some aspects, the PEG lipid is present in a range of about 1 mol% to about 4 mol%.

[0047] In some aspects, the PEG lipid is DPG-PEG or DSPE-PEG.

[0048] In some aspects, the PEG in DPG-PEG has a molecular weight of about 2000 daltons (DPG-PEG2K). In some aspects, the PEG in DSPE-PEG has a molecular weight of about 2000 daltons (DSPE-PEG2K) or about 3400 daltons (DSPE-PEG3.4K).

[0049] In some aspects, DPG-PEG2K, DSPE-PEG2K, or DSPE-PEG3.4K are present in the range of about 1 mol% to about 2 mol%.

[0050] In some aspects, Lipid 15 is present at about 49.25 mol%, cholesterol at about 29.25 mol%, DSPC at about 20 mol%, and DPG-PEG2K at about 1.5 mol%.

[0051] In some aspects, the lipid nanoparticles have an average diameter of about 60 nm to about 100 nm.

[0052] In some aspects, the lipid nanoparticles have an average diameter of about 80 nm.

[0053] In some aspects, the lipid nanoparticles have a polydispersity index (PDI) of about 0.05 to about 1.

[0054] In some aspects, the lipid nanoparticles have a PDI of about 0.09.

[0055] In some aspects, the lipid nanoparticles have a zeta potential (ZP) of about -30 mV to about +5 mV.

[0056] In some aspects, the lipid nanoparticles have a ZP of about -1.4 mV.

[0057] In some aspects, the above cargo contains one or more nucleic acids.

[0058] In some aspects, the above one or more nucleic acids are DNA.

[0059] In some aspects, one or more of the above nucleic acids are RNA.

[0060] In some aspects, the RNA includes a guide RNA and an RNA encoding a Cas enzyme.

[0061] In some aspects, the above one or more nucleic acids encode a chimeric antigen receptor (CAR).

[0062] In some aspects, the cell targeter is coupled to the lipid of the lipid nanoparticle to form a lipid-cell targeter conjugate.

[0063] In some aspects, the cell targeting agent is coupled to the PEG-lipid.

[0064] In some aspects, the cell targeting group is coupled to DPG-PEG2K, DSPE-PEG2K, or DSPE-PEG3.4K.

[0065] In some aspects, the cell targeting device comprises an antibody or a fragment thereof.

[0066] In some aspects, the cell targeting device includes an antibody.

[0067] In some aspects, the cell targeting device includes a Fab fragment.

[0068] In some aspects, the cell targeter comprises a single variable domain.

[0069] In some aspects, the cell targeting agent binds to a molecule on an immune cell.

[0070] In some aspects, the molecule on the immune cell is selected from the group consisting of CD3, CD4, CD7, and CD8.

[0071] In some aspects, the cell targeting agent binds to a molecule on a hematopoietic stem cell.

[0072] In some aspects, the molecule on the hematopoietic stem cell is selected from the group consisting of CD34, CD105, and CD117.

[0073] In some aspects, the lipid-cell targeting conjugate is present in the lipid nanoparticles in a range of about 0.001 mol% to about 0.5 mol%.

[0074] In some aspects, a composition comprising lipid nanoparticles as described herein and one or more carriers or excipients is provided.

[0075] In some aspects, the above composition is a pharmaceutical composition.

[0076] In some aspects, the carrier or excipient is a pharmaceutically acceptable carrier or excipient.

[0077] In some aspects, a method for delivering nucleic acids to cells of a subject is provided, said method comprising administering lipid nanoparticles described herein or a composition described herein to the subject.

[0078] In some aspects, a method for delivering nucleic acids to immune cells of a subject is provided, comprising administering lipid nanoparticles or a composition described herein to a subject.

[0079] In some aspects, a method for delivering nucleic acids to hematopoietic stem cells of a subject is provided, comprising administering lipid nanoparticles described herein or a composition described herein to a subject.

[0080] In some aspects, the polydispersity index composition is a pharmaceutical composition.

[0081] In some aspects, the lipid nanoparticles described herein or the compositions described herein are used in the manufacture of medicines for delivering nucleic acids to target cells.

[0082] In some aspects, the lipid nanoparticles described herein or the compositions described herein are used in the manufacture of medicines for delivering nucleic acids to immune cells.

[0083] In some aspects, the use of the lipid nanoparticles or the compositions described herein in the manufacture of medicines for delivering nucleic acids to hematopoietic stem cells is provided.

[0084] In some aspects, the composition used is a pharmaceutical composition.

[0085] In some aspects, lipid nanoparticles or compositions described herein are provided for use in delivering nucleic acids to target cells.

[0086] In some aspects, lipid nanoparticles or compositions described herein are provided for use in delivering nucleic acids to immune cells.

[0087] In some aspects, lipid nanoparticles or compositions described herein are provided for use in delivering nucleic acids to hematopoietic stem cells.

[0088] In some aspects, the composition used to deliver nucleic acids to target cells is a pharmaceutical composition.

[0089] In some aspects, a method for treating a disease of a subject is provided, said method comprises administering the lipid nanoparticles described herein, or the composition described herein, or the lipid nanoparticles or the composition for use in delivering nucleic acids to the cells of a subject, to the cells of a subject that require such a composition.

[0090] In some aspects, a method for treating a disease of a subject is provided, said method comprising administering lipid nanoparticles described herein or a composition described herein to immune cells of a subject in need thereof.

[0091] In some aspects, the above administration is to multiple immune cells.

[0092] In some aspects, proteins encoded by one or more nucleic acids placed in the lipid nanoparticles are detected in more than 60% (or even 80%) of immune cells 72 hours after administration of the lipid nanoparticles.

[0093] In some aspects, the protein is detected in more immune cells of the subject 72 hours after administration of lipid nanoparticles compared to another subject administered lipid nanoparticles containing an auxiliary lipid present at 10 mol%.

[0094] In some aspects, the protein encoded by the one or more nucleic acids disposed on the lipid nanoparticles increases the effector function of the immune cell or multiple immune cells compared to the immune cell or multiple immune cells to which the lipid nanoparticles were not administered.

[0095] In some aspects, a method for treating a disease of a subject is provided, said method comprising administering lipid nanoparticles described herein or a composition described herein to hematopoietic stem cells of a subject in need thereof.

[0096] In some aspects, the lipid nanoparticles are administered to a plurality of hematopoietic stem cells of the subject.

[0097] In some aspects, a protein encoded by one or more nucleic acids disposed on the lipid nanoparticles is detected in at least 80% of the hematopoietic stem cells of the subject.

[0098] In some aspects, the protein is detected in about 20% of hematopoietic stem cells administered lipid nanoparticles containing an auxiliary lipid present at 10 mol%.

[0099] In some aspects, the administered composition is a pharmaceutical composition.

[0100] In some aspects, lipid nanoparticles or compositions described herein are provided for use in treating a disease in subjects requiring treatment of the disease.

[0101] In some aspects, lipid nanoparticles or compositions described herein are provided for use in treating immune cell-related diseases in subjects requiring treatment for immune cell-related diseases.

[0102] In some aspects, lipid nanoparticles or compositions described herein are provided for use in treating hematopoietic stem cell-related diseases in subjects requiring treatment for hematopoietic stem cell-related diseases.

[0103] In some aspects, the hematopoietic stem cell-related disease mentioned above is sickle cell disease.

[0104] In some aspects, a composition for use in treating a disease of a subject, an immune cell-related disease, or a hematopoietic stem cell-related disease is a pharmaceutical composition. Brief explanation of the drawing

[0105] FIGS. 1a and FIGS. 1b It demonstrates sustained high-efficiency transfection of T cells using lipid nanoparticles containing different amounts of DSPC over a period of 72 hours. Fig. 1a It shows the percentage of CAR-positive T cells after transfection using lipid nanoparticles containing different amounts of DSPC. Fig. 1b This shows the mean fluorescence intensity (MFI) of CD8-positive T cells CAR after transfection with lipid nanoparticles containing different amounts of DSPC. FIGS. 2a to 2c It shows the apoptosis efficiency of T cells transfected with LNPs containing different amounts of DSPC. Fig. 2a It shows the percentage of Nalm6 target cells that died after co-culture with T cells transfected with LNPs containing different amounts of DSPC. Fig. 2b It shows the percentage of CAR-positive cells in T cells transfected with LNPs containing different amounts of DSPC and used in the apoptosis analysis of Figure 2a. Fig. 2cIt shows the mean fluorescence intensity (MFI) of CD8-positive cells in T cells transfected with LNPs containing different amounts of DSPC and used in the apoptosis analysis of Fig. 2a. FIGS. 3a to 3c It shows the elimination of Nalm6 target cells over 16 days in co-culture with CD8+ T cells transfected with LNPs containing different amounts of DSPC. Fig. 3a This shows the average fluorescence of Nalm6 target cells expressing red fluorescent protein over a period of 16 days in the presence of CD8+ T cells transfected with LNP containing different amounts of DSPC. The red arrow indicates that Nalm6 target cells were added to the co-culture; the orange arrow indicates that LNP was added to the co-culture. Fig. 3b This shows the total number of Nalm6 target cells in the co-culture on day 16. Fig. 3c This shows the percentage of surviving CD8+ T cells among lymphocytes in the co-culture on day 16. FIGS. 4a to 4f It shows the transfection efficiency of lipid nanoparticles containing different amounts of DSPC in T cells from different donors. Fig. 4a It shows the percentage of CAR-positive CD8+ T cells from one donor after transfection using lipid nanoparticles containing different amounts of DSPC. Fig. 4b It shows the mean fluorescence intensity (MFI) of CD8-positive T cells from the same donor after transfection with lipid nanoparticles containing different amounts of DSPC. Fig. 4c It shows the percentage of CAR-positive CD8+ T cells from the second donor after transfection using lipid nanoparticles containing different amounts of DSPC. Fig. 4d This shows the mean fluorescence intensity (MFI) of CD8-positive T cells from a second donor after transfection using lipid nanoparticles containing different amounts of DSPC. Fig. 4eIt shows the CAR mean fluorescence intensity (MFI) of CAR-positive T cells from the first donor after transfection with lipid nanoparticles containing different amounts of DSPC. Fig. 4f This shows the CAR mean fluorescence intensity (MFI) of CAR-positive T cells from a second donor after transfection with lipid nanoparticles containing different amounts of DSPC. Luciferase reporter as a Luc-negative control. FIGS. 5a to 5c It shows the fluorescence intensity of CAR-positive T cells bound to CAR targets that have been transfected with lipid nanoparticles containing different amounts of DSPC and immobilized. Fig. 5a It shows the MFI results 24 hours after T cell transfection using LNPs containing different amounts of DSPC. Fig. 5b It shows the MFI results 48 hours after T cell transfection using LNPs containing different amounts of DSPC. Fig. 5c It shows the MFI results 72 hours after T cell transfection using LNPs containing different amounts of DSPC. FIGS. 5a to 5c From: The MFI histogram shows untreated, 10% DSPC, 12.5% ​​DSPC, 15% DSPC, and 20% DSPC from left to right. Figures 6a and 6b It shows the in vivo transfection efficiency of lipid nanoparticles coated with HSC-specific Fab containing different amounts of DSPC in human hematopoietic stem cells (HSCs). Fig. 6a It shows the percentage of mCherry-positive HSCs in the bone marrow of NSG™ mice engrafted with human HSCs treated with lipid nanoparticles coated with HSC-specific Fab encapsulated with mCherry mRNA. Fig. 6b It shows off-target signals in the liver, spleen, and lungs measured by ELISA and off-target signals in ovarian tissue measured by immunohistochemistry (IHC) in NSG™ mice encapsulated with mCherry mRNA and treated with lipid nanoparticles coated with HSC-specific Fab. Figures 7a and 7b It shows the in vitro transfection efficiency in hematopoietic stem cells. Fig. 7a It shows the in vitro transfection efficiency (expressed as % mCherry positive HSC) using LNP formulation 1 (10% DSPC) and LNP formulation 2 (20% DSPC) at different concentrations (e.g., about 0.01 micrograms / mL to about 1 microgram / mL). Fig. 7b It shows the fluorescence intensity (MFI) after transfection using formulation 1 and formulation 2 containing different amounts of DSPC. Specific details for implementing the invention

[0106] The present disclosure provides lipid nanoparticles and lipid nanoparticle compositions comprising an ionizable lipid, a structural lipid, a PEG lipid, a specific amount of an auxiliary lipid, and optionally a Cargo for highly efficient delivery of Cargo to target cells. In some aspects, the lipid nanoparticles further comprise a cell targeting group that optionally couples to the lipid of the lipid nanoparticles to form a lipid-cell targeting group conjugate. Additionally, a method for preparing the lipid nanoparticles and compositions and a method for delivering Cargo to specific target cells, including immune cells and hematopoietic stem cells, using the same are provided.

[0107] definition

[0108] The term “and / or” as used herein refers to specifically disclosing each of two specified features or components together with or without the other. Accordingly, the term “and / or” as used herein in phrases such as “A and / or B” is intended to include “A and B,” “A or B,” “A (alone),” and “B (alone).” Likewise, the term “and / or” as used in phrases such as “A, B, and / or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). The use of the term “or” implies “and / or” unless explicitly indicated to refer only to alternatives or alternatives are mutually exclusive.

[0109] Unless otherwise understood from the context and usage, the expression “at least one” as used herein includes each of the objects listed following the expression individually and includes various combinations of two or more of the listed objects.

[0110] The terms “approximately” or “about,” applied to one or more values ​​of interest, refer to values ​​within a range of values ​​that are similar to the specified reference value and are 10% or less (greater than 10% or less than 10%) in either direction of the specified reference value, unless otherwise stated or otherwise evident from the context (except where such number exceeds 100% of the possible values). Where the terms “approximately” or “about” are applied to a specific value in this application, values ​​without the terms “approximately” or “about” are also disclosed in this application. Additionally, the term “about” may precede any numerical notation, although not always explicitly stated.

[0111] As described herein, any concentration range, percentage range, ratio range, or integer range includes, unless otherwise indicated, any integer value within the enumerated range and, where appropriate, fractions thereof (e.g., tenths and hundredths of an integer). Descriptions of ranges of values ​​should be deemed to specifically disclose each value within these ranges as well as all possible intermediate ranges. For example, descriptions of ranges from 1 to 6 should be deemed to specifically disclose each value within these ranges, such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as each range it includes, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. These definitions are valid independently of the ranges of the intervals.

[0112] The terms used herein “include / includes,” “including,” “have / has,” “having,” “contain / contains,” or “containing,” “comprise / comprises,” or “comprising” are generally understood to be open and non-restrictive, including their grammatical equivalents, and not to exclude, for example, any elements or steps not further enumerated, unless otherwise specifically stated or understood from the context.

[0113] As used herein, the terms “lipid nanoparticle” or “LNP” refer to nanoparticles comprising a single layer of one or more types of lipids. In some aspects, the lipid nanoparticles have an average diameter of about 400 nm to about 50 nm; or about 400 nm or less, about 350 nm or less, about 300 nm or less, about 250 nm or less, about 200 nm or less, about 150 nm or less, about 100 nm or less, or about 50 nm or less. In some aspects, the nanoparticles have a diameter of about 200 nm to about 50 nm. In some aspects, the nanoparticles have a diameter of about 80 nm.

[0114] The term “total lipids” as used herein refers to the set of ionizable lipids, structural lipids, auxiliary lipids, and PEG lipids present in the lipid nanoparticles described herein.

[0115] As used herein, the term “ionizable lipid” refers to a lipid capable of controlling its charge depending on the environment in which it exists. In some aspects, ionizable lipids include lipids of Formula I, Formula II (Lipid 15), Formula III (KC2), Formula IV (KC3), Formula V, or Formula VI. Other ionizable lipids may be used in the lipid nanoparticles described herein.

[0116] The terms "auxiliary lipid," "neutral lipid," "phospholipid," or "neutral phospholipid" as used herein refer to nonpolar lipids of lipid nanoparticles that provide stability and blood compatibility to lipid nanoparticles and enhance cargo delivery.

[0117] The terms “PEG lipid” or “PEGylated lipid” are used interchangeably herein and refer to one or more lipids modified with polyethylene glycol. As described herein, the PEG lipid may be a free PEG lipid or a PEG lipid that is part of a lipid-cell targeting conjugate.

[0118] As used herein, the term “lipid-cell targeting conjugate” refers to a conjugate of the following general formula: [lipid] - [selective linker] - [cell targeting group] (wherein the lipid may be any lipid described herein, and the cell targeting group may be any cell surface molecular linker described herein). The cell targeting group comprises antibodies or fragments thereof including Fab and scFv, as well as immunoglobulin monovariable domains (e.g., VHH domain, humanized VHH domain, or camelized VH domain, but not limited thereto). The lipid of the lipid-cell targeting conjugate is preferably a PEG lipid.

[0119] As used herein, the term "free PEG lipid" refers to PEG lipids that are not part of a lipid-cell targeter conjugate. For example, free PEG lipids may be part of a lipid blend of lipid nanoparticles. Free PEG lipids can reduce or eliminate non-specific binding through the targeter, for example, when a lipid-immune cell targeter conjugate is included in lipid nanoparticles.

[0120] As used herein, the terms “linker” or “spacer” refer to a peptide that fuses two or more polypeptides or proteins together into a single molecule. The use of linkers to link two or more (poly)peptides is well known in the art. For example, one class of peptide linkers is known as “Gly-Ser” or “GS” linkers, which are essentially composed of glycine (G) and serine (S) residues. Linkers may also be alanine linkers.

[0121] As used herein, the term "coupled" refers to a covalent interaction between two molecules. Therefore, "coupled" includes "covalently coupled."

[0122] As used herein, the term “antibody” refers to any antigen-binding molecule or molecular complex comprising at least one complementarity determining region (CDR) that specifically binds to or interacts with a specific antigen. The term is understood to encompass intact antibodies, their antigen-binding fragments, or optionally modified or engineered Fc fragments. Examples of antigen-binding fragments include Fab, Fab', (Fab')2, Fv, single-chain antibodies (e.g., scFv), minibodies, immunoglobulin single variable domains (e.g., VHH), and diabodies. Examples of modified or engineered antibodies include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies).

[0123] Naturally occurring antibodies typically comprise tetramers. Each of these tetramers typically consists of two identical polypeptide chain pairs, each pair comprising one full-length light chain (typically having a molecular weight of about 25 kDa) and one full-length heavy chain (typically having a molecular weight of about 50 to 70 kDa). As used herein, the terms “heavy chain” and “light chain” refer to any immunoglobulin polypeptide having a variable domain sequence sufficient to confer specificity for a target antigen. The amino-terminal portions of each light chain and heavy chain typically contain a variable domain of about 100 to 110 or more amino acids responsible for antigen recognition. The carboxy-terminal portions of each chain typically define a constant domain responsible for effector function. Accordingly, in a naturally occurring antibody, the full-length heavy-chain immunoglobulin polypeptide comprises a variable domain (VH) and three constant domains (CH1, CH2, and CH3), wherein the VH domain is at the amino-terminus of the polypeptide and the CH3 domain is at the carboxyl-terminus, and the full-length light-chain immunoglobulin polypeptide comprises a variable domain (VL) and a constant domain (CL), wherein the VL domain is at the amino-terminus of the polypeptide and the CL domain is at the carboxyl-terminus.

[0124] Human light chains are typically classified into kappa and lambda light chains, and human heavy chains are typically classified into mu, delta, gamma, alpha, or epsilon, respectively, defining the antibody isotypes as IgM, IgD, IgG, IgA, and IgE. IgG has several subclasses including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has subclasses including, but not limited to, IgM1 and IgM2. IgA is similarly subdivided into subclasses including, but not limited to, IgA1 and IgA2. Within the full-length light and heavy chains, variable and constant domains are typically connected by a "J" region consisting of about 12 or more amino acids, and the heavy chain also includes a "D" region consisting of about 10 or more amino acids. For example, refer to the literature [FUNDAMENTAL IMMUNOLOGY (Paul, W., ed., Raven Press, 2nd ed., 1989)], the entirety of which is incorporated herein by reference. The variable domain of each light chain / heavy chain pair typically forms an antigen-binding site. The variable domain of naturally occurring antibodies typically exhibits the same general structure of a relatively conserved framework region (FR) connected by three hypervariable regions, also known as complementarity determining regions or CDRs. The CDRs from the two chains of each pair are typically aligned by the framework region, which can enable binding to specific epitopes. From the amino-terminus to the carboxyl-terminus, both the light chain and heavy chain variable domains typically contain the FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 domains.

[0125] The term "CDR set" refers to a group of three CDRs occurring in a single variable region capable of binding to an antigen. The precise boundaries of these CDRs have been defined differently depending on the system. The system described by Kabat (Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST (National Institutes of Health, Bethesda, Md. (1987) and (1991))) provides not only a clear residue numbering system applicable to any variable region of an antibody, but also precise residue boundaries defining three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and collaborators (Chothia and Lesk, 1987, J. Mol. Biol. 196: 901-17; Chothia et al., 1989, Nature 342: 877-83) discovered that specific subgroups within the Kabat CDRs assume nearly identical peptide backbone conformations despite exhibiting significant variability at the amino acid sequence level. These subgroups were designated as L1, L2, and L3 or H1, H2, and H3, where "L" and "H" represent light chains, respectively. It represents the and heavy chain regions. These regions may be referred to as Chothia CDRs and have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs that overlap with Kabat CDRs are described in the literature [Padlan, 1995, FASEB J. 9: 133-39; MacCallum, 1996, J. Mol. Biol. 262(5): 732-45; and Lefranc, 2003, Dev. Comp. Immunol. 27: 55-77].Another definition of CDR boundaries may not strictly follow one of the mentioned schemes, but will overlap with the Kabat CDR, and may be shortened or extended in light of predictions or experimental findings that a specific residue or group of residues, or even the entire CDR, does not significantly affect antigen binding. The methods used herein may utilize CDRs defined according to any of these schemes, but in certain aspects, use CDRs defined by Kabat or Chothia. The identification of predicted CDRs using amino acid sequences is well known in the art, as in the literature [Martin, AC. Protein sequence and structure analysis of antibody variable domains, In Antibody Engineering, Vol. 2. Kontermann R., Dubel S., eds. Springer-Verlag, Berlin, p. 33-51 (2010)]. The amino acid sequences of the heavy and / or light chain variable domains may also be examined by other conventional methods to identify the sequence of the CDR, for example, by comparing them with known amino acid sequences of other heavy and light chain variable domains to determine the sequence supervariable region. The numbered sequences may be aligned visually or using an alignment program, such as one of the CLUSTAL program family as described in the literature [Thompson, 1994, Nucleic Acids Res. 22: 4673-80]. Molecular models are typically used to accurately compartmentalize the framework and CDR regions and, accordingly, to correct sequence-based assignments.

[0126] As used herein, the term "Fc" refers to a molecule comprising a sequence of a non-antigen binding fragment generated from the digestion of an antibody or by other means, regardless of whether it is in monomeric or multimeric form, and may include a hinge region. The original immunoglobulin source of the natural Fc is preferably of human origin and may be any immunoglobulin, but IgG1 and IgG2 are preferred. The Fc molecule consists of monomeric polypeptides that can be linked in dimeric or multimeric form by covalent association (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of the natural Fc molecule is 1 to 4 depending on the class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgA2). An example of Fc is a disulfide-linked dimer generated from the papain digestion of IgG. The term "natural Fc" as used herein collectively refers to monomeric, dimeric, and macromeric forms.

[0127] The term "Fab" as used herein refers to the F(ab) fragment of an antibody, which typically comprises one light chain and one heavy chain VH and CH1 domains, wherein the VH-CH1 heavy chain portion of the F(ab) fragment cannot form disulfide bonds with other heavy chain polypeptides. The F(ab) fragment as used herein may also comprise one light chain containing two variable domains separated by an amino acid linker and one heavy chain containing two variable domains and a CH1 domain separated by an amino acid linker. The F(ab') fragment typically comprises one light chain and a portion of one heavy chain containing more constant regions (between the CH1 and CH2 domains), allowing interchain disulfide bonds to be formed between the two heavy chains to form an F(ab')2 molecule.

[0128] As used herein, the term “immunoglobulin single variable domain” refers to an immunoglobulin domain capable of specifically binding to an epitope of an antigen without being paired with additional immunoglobulin variable domains. The binding site of the immunoglobulin single variable domain is formed by a single VH, single VHH, or single VL domain. Thus, the antigen binding site of the immunoglobulin single variable domain is formed by three or fewer CDRs. The single variable domain may be a light chain variable domain sequence (e.g., VL-sequence) or a suitable fragment thereof, insofar as it can form a single antigen binding unit (i.e., a functional antigen binding unit composed essentially of a single variable domain, in which the single antigen binding domain does not need to interact with other variable domains to form a functional antigen binding unit); or a heavy chain variable domain sequence (e.g., VH-sequence or VHH-sequence) or a suitable fragment thereof. For example, the immunoglobulin monovariable domain may be a heavy-chain immunoglobulin monovariable domain such as VH, VHH containing camelized VH or humanized VHH, or "dAb" or dAb (or an amino acid sequence suitable for use as dAb). In some aspects, the immunoglobulin monovariable domain is VHH containing camelized VH or humanized VHH. In some aspects, the monovariable domain is derived from a specific species of shark (e.g., the so-called "IgNAR domain"). In some aspects, the immunoglobulin monovariable domain is the NANOBODY® protein. [Note: NANOBODY® is a registered trademark of Ablynx NV.]

[0129] The term "scFv" as used herein refers to a single-chain antibody comprising a heavy chain variable domain and a light chain variable domain connected by a linker.

[0130] The term "VHH" is used herein in its broadest sense and is not limited to specific biological sources or specific methods of preparation. For example, VHH may be produced by (1) isolating the VHH domain of a naturally occurring heavy-chain antibody; (2) by the expression of a nucleotide sequence encoding a naturally occurring VHH domain; (3) by the "humanization" of a naturally occurring VHH domain or by the expression of a nucleic acid encoding such a humanized VHH domain; (4) by the "camelization" of a naturally occurring VH domain from any animal species, particularly mammalian species such as humans, or by the expression of a nucleic acid encoding such a camelized VH domain; (5) by the "camelization" of a "domain antibody" or "dAb" or by the expression of a nucleic acid encoding such a camelized VH domain; (6) by using synthetic or semi-synthetic techniques to produce a protein, polypeptide, or other amino acid sequence; (7) by producing a nucleic acid encoding VHH using nucleic acid synthesis techniques and then expressing the nucleic acid thus obtained; and / or (8) can be obtained by any combination of the above.

[0131] In some aspects, immunoglobulin sequences of different origins, including mouse, rat, rabbit, donkey, human, and camel immunoglobulin sequences, are used in the cell targeters described herein. Additionally, fully human, humanized, or chimeric sequences may be used in the cell targeters described herein.

[0132] As used herein, the term "humanized antibody" refers to an antibody of wholly or partially non-human origin whose protein sequence has been modified to replace specific amino acids located at corresponding positions in the framework regions of the VH and VL domains within the antibody sequence from humans, for example, in order to evade or minimize the immune response in humans and to increase similarity to antibodies naturally produced in humans. For example, using genetic engineering techniques, the variable domain of a non-human antibody of interest can be combined with the constant domain of a human antibody. In some aspects, the constant domain of the humanized antibody is the human CH and CL domains.

[0133] The term “humanized VHH” as used herein refers to an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VHH domain but is “humanized,” that is, a humanized amino acid sequence in which one or more amino acid residues within the amino acid sequence of the naturally occurring VHH sequence (particularly the framework sequence) are replaced with one or more amino acid residues present at corresponding positions in the VH domain of a human conventional 4-chain antibody.

[0134] As used herein, the term “camelized VH” refers to an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VH domain but is “camelized,” that is, by replacing one or more amino acid residues within the amino acid sequence of the naturally occurring VH domain of a conventional 4-chain antibody with one or more amino acid residues present at corresponding position(s) of the VHH domain of a (camelid) heavy-chain antibody. In some aspects, such “camelized” substitutions form a VH-VL interface and / or are inserted into amino acid positions present therein. In some aspects, the VH sequence used as a starting material or starting point for generating or designing the camelized VH is a VH sequence from a mammal, e.g., a human VH sequence, e.g., the VH3 sequence. However, it should be noted that such a camelized VH can be obtained in any suitable manner and is not strictly limited to a polypeptide obtained using a polypeptide containing a naturally occurring VH domain as a starting material. For example, camelid immunoglobulin sequences and humanized camelid immunoglobulin sequences, or camelid domain antibodies, e.g., camelid dAbs, may be used herein. In some aspects, a single variable immunoglobulin domain is fused to form a multivalent and / or multispecific construct (in the case of multivalent and multispecific polypeptides containing one or more VHH domains).

[0135] As used herein, the term "multivalent" refers to the presence of multiple immunoglobulin monovariable domains within a polypeptide. In some aspects, the polypeptide is "divalent," i.e., two immunoglobulin monovariable domains, or is composed of them. In some aspects, the polypeptide is "trivalent," i.e., three immunoglobulin monovariable domains, or is composed of them. In some aspects, the polypeptide is "tetravalent," i.e. four immunoglobulin monovariable domains, or is composed of them. Accordingly, the polypeptide may be "divalent," "trivalent," "tetravalent," "five-valent," "hexavalent," "hypotenous," "octaneous," "nine-valent," etc., that is, the polypeptide may each contain or be composed of two, three, four, five, six, seven, eight, nine, etc. immunoglobulin monovariable domains. In some aspects, the polyvalent immunoglobulin monovariable domain polypeptide is trivalent. In some aspects, the polyvalent immunoglobulin monovariable domain polypeptide is tetravalent. In some aspects, the polyvalent immunoglobulin monovariable domain polypeptide is pentavalent. In some aspects, the polyvalent immunoglobulin monovariable domain polypeptide may also be multispecific.

[0136] As used herein, the term “multispecific” refers to binding to a plurality of different target molecules (also referred to as antigens). In some aspects, a polyvalent immunoglobulin monovariable domain polypeptide is “bispecific,” “triplespecific,” “quadruplespecific,” etc., that is, it can bind to two, three, four, etc. different target molecules, respectively. For example, the polypeptide may be bispecific-trivalent, such that the polypeptide comprises or consists of three immunoglobulin monovariable domains, wherein two immunoglobulin monovariable domains bind to a first target and one immunoglobulin monovariable domain binds to a second target different from the first target. In some aspects, the polypeptide is trispecific-tetravalent, for example, the polypeptide comprises or consists of four immunoglobulin monovariable domains, for example, one immunoglobulin monovariable domain binds to a first target, two immunoglobulin monovariable domains bind to a second target different from the first target, and one immunoglobulin monovariable domain binds to a third target different from the first and second targets. In some aspects, the polypeptide is trispecific-pentavalent, for example, the polypeptide comprises or consists of five immunoglobulin monovariable domains, for example, two immunoglobulin monovariable domains bind to a first target, two immunoglobulin monovariable domains bind to a second target different from the first target, and one immunoglobulin monovariable domain binds to a third target different from the first and second targets. In some aspects, multispecific immunoglobulin polypeptides are multiparatopic.

[0137] As used herein, the term "multiparatopic" refers to binding to multiple different epitopes on the same target molecule (also referred to as an antigen). In some aspects, a polyvalent immunoglobulin single variable domain polypeptide may therefore be "doubleparatopic," "tripleparatopic," etc., that is, it may bind to two, three, or other different epitopes on the same target molecule.

[0138] The terms "subject" and "patient" as used herein refer to organisms that are preferably mammals (e.g., rodents, primates, horses, bovines, pigs, canids, felines, etc.), and more preferably human.

[0139] As used herein, the term "pharmaceutical composition" refers to a combination of an active agent and an inert or active carrier, which makes the composition particularly suitable for in vivo or in vitro diagnostic or therapeutic use.

[0140] As used herein, the term “pharmaceutically acceptable carrier or excipient” refers to any standard pharmaceutical excipient, such as phosphate-buffered saline solution, water, emulsions (e.g., oil / water or water / oil emulsions), and various types of wetting agents. The composition may also include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, refer to the literature [Remington's The Science and Practice of Pharmacy, 21st Edition, AR Gennaro; Lippincott, Williams & Wilkins, Baltimore, MD, 2006].

[0141] As used herein, the term "effective dose" refers to an amount of a compound (e.g., nucleic acid) sufficient to achieve a beneficial or desired result. The effective dose may be administered as one or more doses, applications, or dosages and is not intended to be limited to a specific formulation or route of administration. The term effective dose may be considered to include a therapeutic and / or prophylactic effective dose of the compound.

[0142] As used herein, the term "therapeutic effective dose" refers to an amount of lipid nanoparticles, e.g., containing nucleic acids, or a composition containing lipid nanoparticles, effective to produce a desired therapeutic effect in at least a subpopulation of cells in mammals, e.g., humans, or subjects (e.g., human subjects), at a reasonable benefit / risk ratio applicable to any medical treatment.

[0143] As used herein, the phrase “preventive effective dose” refers to an amount of lipid nanoparticles, e.g., containing nucleic acids, or a composition containing lipid nanoparticles, effective in producing a desired preventive effect in at least a subpopulation of cells of mammals, e.g., humans, or subjects (e.g., human subjects) by reducing, minimizing, or eliminating the risk of a pathological condition or reducing or minimizing the severity of the pathological condition at a reasonable benefit / risk ratio applicable to any medical treatment.

[0144] The terms "treat," "treating," and "treatment" include any effect resulting in the improvement of a pathological condition, disease, disorder, etc., or the alleviation of symptoms thereof, e.g., alleviation, reduction, control, improvement, or elimination.

[0145] geology

[0146] The present invention provides lipid nanoparticles comprising a lipid blend comprising one or more of the following lipids: ionizable lipids, structural lipids, auxiliary lipids, and PEG lipids.

[0147] In some aspects, ionizable lipids include the structure of chemical formula I:

[0148] [Chemical Formula I]

[0149]

[0150] (Here,

[0151] R 1 , R 2 , and R 3 Each is independently combined or C 1-3 It is an alkylene;

[0152] R 1A , R 2A , and R 3A are each independently combined or C 1-10 It is an alkylene;

[0153] R 1A1 , R 1A2 , R 1A3 , R 2A1 , R 2A2 , R 2A3 , R 3A1 , R 3A2 , and R 3A3 H and C are independently 1-20 Alkyl, C 1-20 Alkenyl, -(CH2) 0-10 C(O)OR a1 , or -(CH2) 0-10 OC(O)R a2 and; R a1 and R a2 C each independently 1-20 alkyl or C 1-20 It is alkenyl; R 3B Is

[0154]

[0155] And,

[0156] R 3B1 C 1-6 It is an alkylene;

[0157] R 3B2 and R 3B3 Each independently H or C 1-6 It is an alkyl).

[0158] In some aspects, ionizable lipids are designed to enable the intracellular delivery of cargo, such as nucleic acids, into the cytoplasmic compartments of target cell types and to rapidly degrade into non-toxic components. The complex functions of ionizable cationic lipids are facilitated by the interactions between the chemistry and geometry of the ionizable lipid head group, the hydrophobic "acyl-tail" group, and the linker connecting the head group and the acyl-tail group.

[0159] In some aspects, the pKa of the ionizable amine head group is designed to be in the range of 6 to 8, e.g., between 6.2 and 7.4, or between 6.7 and 7.2, so that it maintains strong cationicity under acidic formulation conditions (e.g., pH 4 to pH 5.5), is neutral or weakly anionic at physiological pH (7.4), and is cationic in early and late endosome compartments (e.g., pH 5.5 to pH 7).

[0160] In some aspects, the acyl-tail group of an ionizable lipid is designed to enable membrane destabilization through the fusion of lipid nanoparticles and the endosome membrane and structural disturbance. The three-dimensional structure of the acyl-tail (determined by its length, degree of unsaturation, and unsaturation location), along with the relative sizes of the head group and the tail group, is thought to play a role in facilitating membrane fusion and the subsequent escape of lipid nanoparticles from the endosome (a key requirement for the cytoplasmic delivery of nucleic acid cargo). In some aspects, the ionizable lipid comprises a linker connecting the head group and the acyl-tail group, said linker being designed to be degraded by physiologically widespread enzymes (e.g., esterases or proteases) or by acid-catalyzed hydrolysis.

[0161] In some aspects, ionizable lipids include the structure of formula II (Lipid 15):

[0162] [Chemical Formula II]

[0163] .

[0164] In some aspects, ionizable lipids include the structure of chemical formula III (KC2).

[0165] [Chemical Formula III]

[0166] .

[0167] In some aspects, ionizable lipids include the structure of chemical formula IV (KC3):

[0168] [Chemical Formula IV]

[0169] .

[0170] In some aspects, the ionizable lipid comprises the structure of formula V:

[0171] [Chemical Formula V]

[0172]

[0173] (Here, R 1 and R 2 Each is independently a lipid).

[0174] In some aspects, the ionizable lipid comprises the structure of formula VI:

[0175] [Chemical Formula VI]

[0176]

[0177] (Here, R 1 and R 2 Each is independently a lipid).

[0178] In some embodiments, where the ionizable lipid comprises the structure of Formula V or Formula VI, R 1 and R 2 Each is independently a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkenyl. In some embodiments, where the ionizable lipid comprises the structure of Formula V or Formula VI, R 1 and R 2is the same lipid. In some embodiments, where the ionizable lipid comprises the structure of Formula V or Formula VI, R 1 and R 2 is a different lipid. In some embodiments, the lipid is a hydrocarbon (e.g., substituted or unsubstituted, saturated or unsaturated, branched or unbranched hydrocarbon). The hydrocarbon may be an alkane, an alkene, or an alkyne. In some embodiments, the hydrocarbon chain is saturated or unsaturated. In certain embodiments, the unsaturated hydrocarbon chain comprises at least one, at least two, at least three, at least four, at least five, or at least six carbon-carbon double bonds (e.g., cis double bonds and / or trans double bonds). In some embodiments, the lipid is a substituted or unsubstituted C 7-36 It is an alkyl. In certain embodiments, the lipid is a substituted or unsubstituted C 7-36 It is an alkenyl. In certain embodiments, the lipid is an unsubstituted C 7-36 Alkyl or unsubstituted C 7-36 It is an alkenyl. In certain embodiments, the hydrocarbon is substituted with alkyl, alkenyl, alkynyl, amino, alkylamino, dialkylamino, trialkylamino, hydroxyl, alkoxy, carbonyl, halogen, aryl, heterocyclic, aromatic heterocyclic, cyano, amide, carbamoyl, carboxylic acid, ester, thioether, alkylthioether, thiol, ureido, or a combination thereof. Each of these groups may be substituted again. In some embodiments, the hydrocarbon is substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, or more than 10 substituents.

[0179] In some aspects, the ionizable lipid is International PCT publication No. WO 2009028824A2, WO 2011043913A2, WO 2012091523A2, WO 2015074085A1, WO 2016081029A1, WO 2017117530A1, WO 2018118102A1, WO 2018119163A1, WO 2019045897A1, WO 2020069445A1, WO 2020106903A1, WO 2020219876A1, WO 2021055892A1, WO 2021163339A1, WO 2021188389A2, WO 2021202694A1, WO 2022016070A1, WO 2022119883A2, WO 2022120388A2, WO 2022159475A1, WO 2022207938A1, WO 2022218957A1, WO 2022246555A1, WO 2023023410A2, WO 2023091490A1, WO 2023091787A1, WO 2023114937A2, WO 2023114944A1, WO 2023115221A1, WO 2023121970A1, WO 2023121975A1, WO One or more lipids described in 2023141624A1, WO 2023144798A1, WO 2023183616A1, WO 2023196444A1, WO 2023196527A2, WO 2023207101A1, WO 2023235589A1, WO 2023240156A1, WO 2024008967A1, WO 2024010330A1, WO 2024019770A1, and WO 2024035710A2. In another aspect, the ionizable lipid comprises one or more lipids described in the literature [Semple, S., Akinc, A., Chen, J. et al. Rational design of cationic lipids for siRNA delivery. It contains one or more lipids described in Nat Biotechnol 28, 172-176 (2010).

[0180] In some aspects, ionizable lipids are present in the lipid blend of lipid nanoparticles in a range of about 20 mol% to about 70 mol%.

[0181] In some aspects, ionizable lipids are present in the lipid blend of lipid nanoparticles in a range of about 20 mol% to about 50 mol%. In some aspects, ionizable lipids are present in the lipid blend of lipid nanoparticles at about 20 mol%, about 21 mol%, about 22 mol%, about 23 mol%, about 24 mol%, about 25 mol%, about 26 mol%, about 27 mol%, about 28 mol%, about 29 mol%, about 30 mol%, about 31 mol%, about 32 mol%, about 33 mol%, about 34 mol%, about 35 mol%, about 36 mol%, about 37 mol%, about 38 mol%, about 39 mol%, about 40 mol%, about 41 mol%, about 42 mol%, about 43 mol%, about 44 mol%, about 45 mol%, about 46 mol%, about 47 mol%, about 48 mol%, about 49 mol%, about 50 mol%, about 51 mol%, and about 52 It exists in mol%, about 53 mol%, about 54 mol%, about 55 mol%, about 56 mol%, about 57 mol%, about 58 mol%, about 59 mol%, about 60 mol%, about 61 mol%, about 62 mol%, about 63 mol%, about 64 mol%, about 65 mol%, about 66 mol%, about 67 mol%, about 68 mol%, about 69 mol%, or about 70 mol%.

[0182] In some aspects, ionizable lipids are present in the lipid blend of lipid nanoparticles in a range of about 25 mol% to about 65 mol%; about 30 mol% to about 60 mol%; about 35 mol% to about 55 mol%; or about 40 mol% to about 50 mol%. In some aspects, ionizable lipids are present in the lipid blend of lipid nanoparticles in a range of about 40 mol% to about 60 mol%; about 45 mol% to about 55 mol%; or about 48 mol% to about 50 mol%. In some aspects, ionizable lipids are present in the lipid blend of lipid nanoparticles at about 49 mol%. In some aspects, the lipid blend of lipid nanoparticles comprises at least 20 mol% of ionizable lipids. In some aspects, the lipid blend of lipid nanoparticles comprises at least 30 mol% of ionizable lipids. In some aspects, the lipid blend of lipid nanoparticles comprises at least 40 mol% of ionizable lipids. In some aspects, the lipid blend of lipid nanoparticles comprises at least 50 mol% of ionizable lipids.

[0183] In some aspects, lipid nanoparticles contain one or more auxiliary lipids. In some aspects, the auxiliary lipid is a phospholipid. In some aspects, the auxiliary lipid is a neutral phospholipid. In some aspects, the auxiliary lipid is phosphatidylcholine, phosphatidylethanolamine, distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), hydrogenated soybean phosphatidylcholine (HSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), sphingomyelin (SM), dimyristoyl-phosphatidylethanolamine (DMPE), dilinoleoyl-glycero-phosphocholine (DLPC), dimyristoyl-glycero-phosphocholine (DMPC), dipalmitoyl-glycero-phosphocholine (DPPC), diundecanoyyl-glycero-phosphocholine (DUPC), It is selected from the group consisting of palmitoyl-oleoyl-glycero-phosphocholine (POPC), dioctadecenyl-glycero-phosphocholine, oleoyl-cholesterylhemisuccinoyl-glycero-phosphocholine, hexadecyl-glycero-phosphocholine, dilinolenoyl-glycero-phosphocholine, diarachidonoyl-glycero-3-phosphocholine, didocosahexaenoyl-glycero-phosphocholine, or sphingomyelin.

[0184] In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles in a range of about 10 mol% to about 50 mol%. In some aspects, the auxiliary lipid is in the lipid blend of lipid nanoparticles at about 10 mol%, about 11 mol%, about 12 mol%, about 13 mol%, about 14 mol%, or about 15 mol%, about 16 mol%, about 17 mol%, about 18 mol%, about 19 mol%, about 20 mol%, about 21 mol%, about 22 mol%, about 23 mol%, about 24 mol%, about 25 mol%, about 26 mol%, about 27 mol%, about 28 mol%, about 29 mol%, about 30 mol%, about 31 mol%, about 32 mol%, about 33 mol%, about 34 mol%, about 35 mol%, about 36 mol%, about 37 mol%, about 38 mol%, about 39 mol%, about 40 mol%, about 41 mol%, about 42 It is present in mol%, about 43 mol%, about 44 mol%, about 45 mol%, about 46 mol%, about 47 mol%, about 48 mol%, about 49 mol%, or about 50 mol%. In some aspects, the auxiliary lipid is present in the lipid blend of lipid nanoparticles in the range of about 16 mol% to about 50 mol%. In some aspects, the auxiliary lipid is present in the lipid blend of lipid nanoparticles in about 16 mol% to about 40 mol%. In some aspects, the auxiliary lipid is present in the lipid blend of lipid nanoparticles in about 16 mol% to about 35 mol%. In some aspects, the auxiliary lipid is present in the lipid blend of lipid nanoparticles in about 16 mol% to about 30 mol%. In some aspects, the auxiliary lipid is present in the lipid blend of lipid nanoparticles in about 16 mol% to about 25 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 16 mol% to about 20 mol%.In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 18 mol% to about 25 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 18 mol% to about 22 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 20 mol% to about 40 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 20 mol% to about 35 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 20 mol% to about 30 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 20 mol% to about 25 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 25 mol% to about 40 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 25 mol% to about 35 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 25 mol% to about 30 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 30 mol% to about 40 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 30 mol% to about 35 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 20 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 30 mol%. In some aspects, auxiliary lipids are present in the lipid blend of lipid nanoparticles at about 40 mol%. In some aspects, the lipid blend of lipid nanoparticles comprises at least 15 mol% of auxiliary lipids. In some aspects, the lipid blend of lipid nanoparticles contains at least 20 mol% of auxiliary lipid.In some aspects, the lipid blend of lipid nanoparticles contains at least 30 mol% of auxiliary lipid.

[0185] In some aspects, the auxiliary lipid of the lipid nanoparticles is DSPC.

[0186] In some aspects, lipid nanoparticles contain one or more PEG lipids.

[0187] In some aspects, the PEG lipid is PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, or PEG-modified dialkylglycerol.

[0188] In some aspects, PEG lipids are dioleoylglycerol-PEG (DOG-PEG), dimyristoyl-glycerol-PEG (DMG-PEG), dipalmitoyl-glycerol-PEG (DPG-PEG), dilinoleoyl-glycero-phosphatidyl ethanolamine-PEG (DLPE-PEG), dimyristoyl-phosphatidyl ethanolamine-PEG (DMPE-PEG), dipalmitoyl-phosphatidyl ethanolamine-PEG (DPPE-PEG), distearoylglycerol-PEG (DSG-PEG), diacylglycerol-PEG (DAG-PEG), dimyristoyl-glycerol-PEG (DMG-PEG), dipalmitoyl-glycerol-PEG (DPG-PEG), distearoylglycerol-PEG (DSG-PEG), PEG-ceramide, distearoyl-glycero-phosphoglycerol-PEG (DSPG-PEG), It is selected from the group consisting of dioleoyl-glycero-phosphoethanolamine-PEG (DOPE-PEG), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, and distearoyl-phosphatidylethanolamine-PEG (DSPE-PEG), DSPE-PEG-cysteine, or derivatives thereof. In some aspects, the PEG lipid comprises diacylphosphatidylethanolamine comprising dipalmitoyl (C16) chains or distearoyl (C18) chains.

[0189] In some aspects, PEG lipids are present in lipid blends of lipid nanoparticles in a range of about 1 mol% to about 10 mol%, about 1 mol% to about 9 mol%, about 1 mol% to about 8 mol%, about 1 mol% to about 7 mol%, about 1 mol% to about 6 mol%, about 1 mol% to about 5 mol%, about 1 mol% to about 4 mol%, and about 1 mol% to about 3 mol%. In some aspects, PEG lipids are present in the lipid blend of lipid nanoparticles in a range of about 2 mol% to about 10 mol%, about 2 mol% to about 9 mol%, about 2 mol% to about 8 mol%, about 2 mol% to about 7 mol%, about 2 mol% to about 6 mol%, about 2 mol% to about 5 mol%, about 2 mol% to about 4 mol%, about 2 mol% to about 3 mol%, or about 1 mol%, about 2 mol%, about 3 mol%, about 4 mol%, or about 5 mol%. In some aspects, the PEG lipids are free PEG lipids.

[0190] In some aspects, PEG lipids are present in a lipid blend of lipid nanoparticles in an amount of about 0.01 mol% to about 10 mol%, about 0.01 mol% to about 5 mol%, about 0.01 mol% to about 4 mol%, about 0.01 mol% to about 3 mol%, about 0.01 mol% to about 2 mol%, about 0.01 mol% to about 1 mol%, about 0.1 mol% to about 10 mol%, about 0.1 mol% to about 5 mol%, about 0.1 mol% to about 4 mol%, about 0.1 mol% to about 3 mol%, about 0.1 mol% to about 2 mol%, about 0.1 mol% to about 1 mol%, about 0.5 mol% to about 10 mol%, about 0.5 mol% to about 5 mol%, about 0.5 mol% to about 4 mol%, about 0.5 mol% to about 0.5 mol%. It is present in the range of 3 mol%, about 0.5 mol% to about 2 mol%, about 0.5 mol% to about 1 mol%, about 1 mol% to about 2 mol%, about 3 mol% to about 4 mol%, about 4 mol% to about 5 mol%, or about 5 mol% to about 6 mol%. In some aspects, PEG lipids are present in the lipid blend of lipid nanoparticles in an amount of about 0.5 mol%, about 1 mol%, about 1.5 mol%, about 2 mol%, about 2.5 mol%, about 3 mol%, about 3.5 mol%, about 4 mol%, about 4.5 mol%, about 5 mol%, or about 5.5 mol%. In some aspects, the PEG lipid is free PEG lipid.

[0191] In some aspects, PEG lipids are present in the lipid blend of lipid nanoparticles in a range of about 0.1 mol% to about 4 mol%. In some aspects, PEG lipids are present in the lipid blend of lipid nanoparticles in a range of about 0.5 mol% to about 3.5 mol%, about 0.75 mol% to about 3 mol%, about 1 mol% to about 2.5 mol%, and about 1.5 mol% to about 2 mol%. In some aspects, PEG lipids are present in lipid blends of lipid nanoparticles at about 0.1 mol%, about 0.2 mol%, about 0.3 mol%, about 0.4 mol%, about 0.5 mol%, about 0.6 mol%, about 0.7 mol%, about 0.8 mol%, about 0.9 mol%, about 1 mol%, about 1.1 mol%, about 1.2 mol%, about 1.3 mol%, about 1.4 mol%, about 1.5 mol%, about 1.6 mol%, about 1.7 mol%, about 1.8 mol%, about 1.9 mol%, about 2 mol%, about 2.1 mol%, about 2.2 mol%, about 2.3 mol%, about 2.4 mol%, about 2.5 mol%, about 2.6 mol%, about 2.7 mol%, about 2.8 mol%, about 2.9 mol%, about It is present in amounts of 3 mol%, about 3.1 mol%, about 3.2 mol%, about 3.3 mol%, about 3.4 mol%, about 3.5 mol%, about 3.6 mol%, about 3.7 mol%, about 3.8 mol%, about 3.9 mol%, or about 4 mol%. In some aspects, PEG lipid is present in the lipid blend of lipid nanoparticles in an amount of about 1.25 mol% to about 1.75 mol%. In some aspects, PEG lipid is present in the lipid blend of lipid nanoparticles in an amount of about 1.5 mol%. In some aspects, the lipid blend of lipid nanoparticles comprises at least 0.5 mol% of PEG lipid. In some aspects, the lipid blend of lipid nanoparticles comprises at least 1 mol% of PEG lipid.In some aspects, the lipid blend of lipid nanoparticles contains at least 2 mol% of PEG lipid.

[0192] In some aspects, lipid nanoparticles comprise one or more structural lipids. In some aspects, the structural lipid is a sterol. In some aspects, one or more sterols are selected from the group consisting of cholesterol, pecosterol, β-sitosterol, ergosterol, campesterol, stigmasterol, stigmasterol, and brassicasterol. In some aspects, the sterol is cholesterol.

[0193] In some aspects, structural lipids are present in the lipid blend of lipid nanoparticles in a range of about 20 mol% to about 70 mol%.

[0194] In some aspects, structural lipids are present in the lipid blend of lipid nanoparticles in a range of about 20 mol% to about 50 mol%. In some aspects, structural lipids are present in the lipid blend of lipid nanoparticles at approximately 20 mol%, approximately 21 mol%, approximately 22 mol%, approximately 23 mol%, approximately 24 mol%, approximately 25 mol%, approximately 26 mol%, approximately 27 mol%, approximately 28 mol%, approximately 29 mol%, approximately 30 mol%, approximately 31 mol%, approximately 32 mol%, approximately 33 mol%, approximately 34 mol%, approximately 35 mol%, approximately 36 mol%, approximately 37 mol%, approximately 38 mol%, approximately 39 mol%, approximately 40 mol%, approximately 41 mol%, approximately 42 mol%, approximately 43 mol%, approximately 44 mol%, approximately 45 mol%, approximately 46 mol%, approximately 47 mol%, approximately 48 mol%, approximately 49 mol%, approximately 50 mol%, approximately 51 mol%, and approximately 52 It exists in mol%, about 53 mol%, about 54 mol%, about 55 mol%, about 56 mol%, about 57 mol%, about 58 mol%, about 59 mol%, about 60 mol%, about 61 mol%, about 62 mol%, about 63 mol%, about 64 mol%, about 65 mol%, about 66 mol%, about 67 mol%, about 68 mol%, about 69 mol%, or about 70 mol%.

[0195] In some aspects, structural lipids are present in the lipid blend of lipid nanoparticles in a range of about 20 mol% to about 65 mol%; about 20 mol% to about 60 mol%; about 20 mol% to about 55 mol%; or about 25 mol% to about 50 mol%, or about 25 mol% to about 45 mol%, or about 20 mol% to about 40 mol%. In some aspects, structural lipids are present in the lipid blend of lipid nanoparticles in about 20%, about 30 mol%, about 40 mol%, or about 50 mol%. In some aspects, structural lipids are present in the lipid blend of lipid nanoparticles in about 29 mol%. In some aspects, structural lipids are present in the lipid blend of lipid nanoparticles in about 39 mol%. In some aspects, the lipid blend of lipid nanoparticles comprises at least 20 mol% of structural lipids. In some aspects, the lipid blend of lipid nanoparticles contains at least 25 mol% of structural lipids. In some aspects, the lipid blend of lipid nanoparticles contains at least 30 mol% of structural lipids.

[0196] In some aspects, the lipid nanoparticles comprise ionizable lipids present in a range of about 30 mol% to about 70 mol% in the lipid blend of the lipid nanoparticles; auxiliary lipids present in a range of about 10 mol% to about 50 mol% in the lipid blend of the lipid nanoparticles; structural lipids present in a range of about 20 mol% to about 70 mol% in the lipid blend of the lipid nanoparticles; PEG lipids present in a range of about 1 mol% to about 10 mol% in the lipid blend of the lipid nanoparticles, and optionally Cargo.

[0197] In some aspects, the lipid nanoparticles comprise ionizable lipids present in a range of about 40 mol% to about 60 mol% in the lipid blend of the lipid nanoparticles; auxiliary lipids present in a range of about 16 mol% to about 40 mol% in the lipid blend of the lipid nanoparticles; structural lipids present in a range of about 20 mol% to about 50 mol% in the lipid blend of the lipid nanoparticles; PEG lipids present in a range of about 1 mol% to about 5 mol% in the lipid blend of the lipid nanoparticles, and optionally Cargo.

[0198] In some aspects, the lipid nanoparticles comprise ionizable lipids present in a range of about 48 mol% to about 50 mol% in the lipid blend of the lipid nanoparticles; auxiliary lipids present in a range of about 16 mol% to about 40 mol% in the lipid blend of the lipid nanoparticles; structural lipids present in a range of about 20 mol% to about 40 mol% in the lipid blend of the lipid nanoparticles; PEG lipids present in a range of about 1 mol% to about 2 mol% in the lipid blend of the lipid nanoparticles, and optionally Cargo.

[0199] In some aspects, the lipid nanoparticles comprise: an ionizable lipid selected from the group consisting of Formula II (Lipid 15), Formula III (KC2), Formula IV (KC3), Formula V, and Formula VI, present in a range of about 30 mol% to about 70 mol% in the lipid blend of the lipid nanoparticles; an auxiliary lipid that is DSPC and present in a range of about 10 mol% to about 50 mol% in the lipid blend of the lipid nanoparticles; a structural lipid that is cholesterol and present in a range of about 20 mol% to about 70 mol% in the lipid blend of the lipid nanoparticles; a PEG lipid that is DPG-PEG2K and present in a range of about 1 mol% to about 10 mol% in the lipid blend of the lipid nanoparticles; and optionally a cargo.

[0200] In some aspects, the lipid nanoparticles comprise an ionizable lipid selected from the group consisting of Formula II (Lipid 15), Formula III (KC2), Formula IV (KC3), Formula V, and Formula VI, present in a range of about 40 mol% to about 60 mol% in the lipid blend of the lipid nanoparticles; an auxiliary lipid that is DSPC and present in a range of about 16 mol% to about 40 mol% in the lipid blend of the lipid nanoparticles; a structural lipid that is cholesterol and present in a range of about 20 mol% to about 50 mol% in the lipid blend of the lipid nanoparticles; a PEG lipid that is DPG-PEG2K and present in a range of about 1 mol% to about 5 mol% in the lipid blend of the lipid nanoparticles, and optionally a cargo.

[0201] In some aspects, the lipid nanoparticles comprise an ionizable lipid selected from the group consisting of Formula II (Lipid 15), Formula III (KC2), Formula IV (KC3), Formula V, and Formula VI, present in a range of about 48 mol% to about 50 mol% in the lipid blend of the lipid nanoparticles; an auxiliary lipid that is DSPC and present in a range of about 16 mol% to about 20 mol% in the lipid blend of the lipid nanoparticles; a structural lipid that is cholesterol and present in a range of about 20 mol% to about 40 mol% in the lipid blend of the lipid nanoparticles; a PEG lipid that is DPG-PEG2K and present in a range of about 1 mol% to about 2 mol% in the lipid blend of the lipid nanoparticles, and optionally a cargo.

[0202] In some aspects, the lipid nanoparticles comprise an ionizable lipid selected from the group consisting of Formula II (Lipid 15), Formula III (KC2), Formula IV (KC3), Formula V, and Formula VI, present in an amount of about 49.24 mol% in the lipid blend of the lipid nanoparticles; an auxiliary lipid that is DSPC and present in an amount of about 20 mol% in the lipid blend of the lipid nanoparticles; a structural lipid that is cholesterol and present in an amount of about 29.25 mol% in the lipid blend of the lipid nanoparticles; a PEG lipid that is DPG-PEG2K and present in an amount of about 1.51 mol% in the lipid blend of the lipid nanoparticles; and optionally a cargo.

[0203] In some aspects, when the lipid nanoparticles comprise a lipid blend, the value of mol% refers to the mol% within the lipid blend. For example, when the nanoparticles comprise a lipid blend comprising ionizable lipids, structural lipids, auxiliary lipids, and PEG lipids, the sum of the mol% of ionizable lipids, the mol% of structural lipids, the mol% of auxiliary lipids, and the mol% of PEG lipids is 100%.

[0204] Cell targeting device

[0205] In some aspects, the lipid nanoparticles described herein comprise a cell targeting group conjugated to the lipid of said lipid nanoparticles. In some aspects, the lipid nanoparticle comprises one or more cell targeting groups conjugated to the lipid of said lipid nanoparticles. In some aspects, the cell targeting group comprises an antibody. In some aspects, said antibody is a human antibody or a humanized antibody. In some aspects, the cell targeting group comprises an antibody fragment without an Fc component. In some aspects, the cell targeting group comprises an antigen-binding fragment selected from the group consisting of Fab, F(ab')2, Fab'-SH, Fv, scFv fragments, or an immunoglobulin single variable domain. In some aspects, the cell targeting group comprises Fab. In some aspects, the cell targeting group comprises an immunoglobulin single variable domain.

[0206] In some aspects, the cell targeting unit comprises one or more immunoglobulin single variable domains. In some aspects, the cell targeting unit comprises one or more antibody fragments, such as Fab, scFv, or a combination thereof.

[0207] In some aspects, the cell targeting agent is a monovalent, multivalent, or multispecific polypeptide. In some aspects, the cell targeting agent comprises a multivalent and multispecific polypeptide containing one or more antibodies, one or more immunoglobulin monovariable domains, such as one or more VHH domains, and / or one or more Fabs, and / or one or more scFvs.

[0208] In some aspects, the multivalent cell targeter comprises two or more immunoglobulin monovariable domains, Fab, or scFv that target the same antigen, e.g., the same portion or epitope of said antigen, or two or more different portions or epitopes of said antigen. In some aspects, the multivalent cell targeter comprises two or more immunoglobulin monovariable domains, Fab, or scFv that target different antigens. In some aspects, the multivalent cell targeter comprises a combination of immunoglobulin monovariable domains, Fab, or scFv that some target the same antigen and some target different antigens.

[0209] In some aspects, the bivalent cell targeter comprises a first immunoglobulin monovariable domain, Fab, or scFv, that targets a first portion or epitope of an antigen, and a second immunoglobulin monovariable domain, Fab, or scFv, that targets the same portion or epitope of said antigen or a different portion or epitope of said antigen. In some aspects, the bivalent cell targeter comprises a first immunoglobulin monovariable domain, Fab, or scFv, that targets a first antigen, and a second immunoglobulin monovariable domain, Fab, or scFv, that targets a second antigen different from said first antigen.

[0210] In some aspects, the trivalent cell targeter comprises three identical or different immunoglobulin monovariable domains, Fab, or scFv, that target identical or different portions or epitopes of the same antigen. In some aspects, the trivalent cell targeter comprises two identical or different immunoglobulin monovariable domains, Fab, or scFv, that target identical or different portions or epitopes on a first antigen, and a third immunoglobulin monovariable domain that targets a second antigen different from the first antigen.

[0211] In some aspects, the trivalent cell targeting device comprises a first immunoglobulin monovariable domain, Fab, or scFv, that targets a first antigen, a second immunoglobulin monovariable domain, Fab, or scFv, that targets a second antigen different from the first antigen, and a third immunoglobulin monovariable domain, Fab, or scFv, that targets a third antigen different from the first antigen and the second antigen.

[0212] In some aspects, the cell targeting unit comprises one or more immunoglobulin monovariable domains, Fab, or scFv, and optionally further comprises one or more additional amino acid sequences (all optionally linked via one or more suitable linkers).

[0213] In some aspects, the cell targeting site additionally comprises one or more other groups, residues, moieties, or binding units. These additional groups, residues, moieties, binding units, or amino acid sequences may or may not provide additional function to the immunoglobulin monovariable domain, Fab, or scFv (and / or the polypeptide in which they exist), and may or may not alter the properties of the immunoglobulin monovariable domain, Fab, or scFv.

[0214] In some aspects, these additional groups, residues, moiety, or binding units may be one or more additional amino acids, and accordingly, the cell targeting group is a (fusion) protein or a (fusion) polypeptide. In some aspects, the one or more other groups, residues, moiety, or binding units are immunoglobulins. In some aspects, the one or more other groups, residues, moiety, or binding units are domain antibodies (dAb), amino acids suitable for use as domain antibodies, immunoglobulin monovariable domains, amino acids suitable for immunoglobulin monovariable domains, Fab, amino acids suitable for Fab, scFv, or amino acids suitable for scFv.

[0215] In some aspects, these groups, residues, moiety, or binding units may be chemical groups, residues, or moietys that may or may not be biologically and / or pharmacologically active in themselves. In some aspects, these groups are linked to an immunoglobulin monovariable domain, Fab, or scFv to provide a "derivative" of the immunoglobulin monovariable domain, Fab, or scFv. In some aspects, the additional residue may be effective in preventing or reducing the binding of so-called "previous antibodies" to the polypeptide. To this end, the polypeptide and construct may contain a C-terminal extension (X)n, where n is 1 to 10, 1 to 5, 2, or 1; each X is an amino acid residue (preferably naturally occurring) independently selected and preferably independently selected from the group consisting of alanine (A), glycine (G), valine (V), leucine (L), or isoleucine (I). In some aspects, X is not cysteine.

[0216] In the cell targeting unit, one or more immunoglobulin monovariable domains, Fabs, or scFvs and one or more groups, residues, moieties, or binding units may be linked to each other directly and / or through one or more suitable linkers. For example, if one or more groups, residues, moieties, or binding units are amino acids, the linker may also be an amino acid, and the resulting polypeptide is a fusion protein or fusion polypeptide.

[0217] In some aspects, the linker comprises one or more repeats of a peptide motif, such as a GS motif, for example. In some aspects, the linker comprises a GGGGS motif (SEQ ID NO: 2) (e.g., having the chemical formula (Gly-Gly-Gly-Gly-Ser)n, where n can be 1, 2, 3, 4, 5, 6, 7, or more). In some aspects, the linker is a 9GS linker (GGGGSGGGS) (SEQ ID NO: 5), a 15GS linker (n=3), and a 35GS linker (n=7). For example, see references [Chen et al. 2013 (Adv. Drug Deliv. Rev. 65(10): 1357-1369) and Klein et al. See 2014 (Protein Eng. Des. Sel. 27 (10): 325-330). In some aspects, the linker is a 3A linker, that is, a linker containing three alanines. In some aspects, the linker is a 5GS linker, 7GS linker, 8GS linker, 9GS linker, 10GS linker, 15GS linker, 18GS linker, 20GS linker, 25GS linker, 30GS linker, 35GS linker, or 40GS linker as presented in Table 1 below.

[0218]

[0219] Cell targeting device that targets immune cells

[0220] In some aspects, a cell targeter or a combination of targeters may be selected based on the desired localization, function, or structural features of a given target cell. For example, a cell targeter may target T cells, T cell populations, or T cell subpopulations. In some aspects, a cell targeter targeting T cells comprises one or more antibodies, immunoglobulin monovariable domains, Fab, scFv, or derivatives thereof that target T cell surface antigens. Exemplary T cell surface antigens include, but are not limited to, CD3, CD4, CD7, and CD8.

[0221] An exemplary CD3 binder (CD3γ / δ / ε, CD3γ, CD3δ, CD3γ / ε, CD3δ / ε, or CD3ε) may be an antibody selected from the group consisting of MEM-57 (CD3γ / δ / ε, EnzoLife Sciences), MAB100 (CD3ε, R&D Systems), CD3-H5 (CD3ε, Abnova Corporation), CD3-12 (CD3ε, Cell Signaling Technology), LE-CD3 (CD3ε, Santa Cruz Biotechnology, Inc.), NBP1-31250 (CD3γ, Novus Biologicals), 16669-1-AP (CD3δ, Invitrogen) and antigen-binding fragments thereof. In some aspects, the binder comprises the VH domain and VL domain of an antibody selected from the group consisting of MEM-57 (CD3γ / δ / ε, EnzoLife Sciences), MAB100 (CD3ε, R&D Systems), CD3-H5 (CD3ε, Abnova Corporation), CD3-12 (CD3ε, Cell Signaling Technology), LE-CD3 (CD3ε, Santa Cruz Biotechnology, Inc.), NBP1-31250 (CD3γ, Novus Biologicals), and 16669-1-AP (CD3δ, Invitrogen). In some aspects, the binder is Kabat (cf. Kabat et al., (1991) Sequences of Proteins of Immunological Interest, NIH Publication No. 91-3242, Bethesda), Chothia (cf. y, Chothia C & Lesk AM, (1987), J. MOL. BIOL. 196: 901-917), MacCallum (cf. MacCallum RM et al., (1996) J. MOL. BIOL.262: 732-745), or any other CDR determination method known in the art, comprising heavy chain CDR1, CDR2, and CDR3 and light chain CDR1, CDR2, and CDR3 of the VH and VL sequences of antibodies selected from the group consisting of MEM-57 (CD3γ / δ / ε, EnzoLife Sciences), MAB100 (CD3ε, R&D Systems), CD3-H5 (CD3ε, Abnova Corporation), CD3-12 (CD3ε, Cell Signaling Technology), LE-CD3 (CD3ε, Santa Cruz Biotechnology, Inc.), NBP1-31250 (CD3γ, Novus Biologicals), and 16669-1-AP (CD3δ, Invitrogen). Exemplary CD3 binders are also clones hsp34, OKT-3, UCHT1, 38.1, HIT3a, RFT8, SK7, BC3, SP34-2, HU291, TRX4, catumaxomab, teplizumab, 3-106, 3-114, 3-148, 3-190, 3-271, 3-550, 4-10, 4-48, H2C, F12Q, I2C, SP7, 3F3A1, CD3-12, 301, RIV9, JB38-29, JE17-74, GT0013, 4E2, 7A4, 4D10A6, SPV-T3b, M2AB, ICO-90, 30A1, or It may also be selected from an antibody or antibody fragment using the CDR of Hu38E4.v1 (U.S. Patent Application 20200299409A1), REGN5458 (U.S. Patent Application 20200024356A1), or blinatumomab.

[0222] An exemplary CD4 conjugate may be an antibody selected from the group consisting of ibalizumab (https: / / www.genome.jp / dbget-bin / www_bget?D09575), AF1856 (R&D Systems), MAB554 (R&D Systems), BF0174 (Affinity Biosciences), PAB31115 (Abnova Corporation), CAL4 (Abcam), and antigen-binding fragments thereof. In some aspects, the conjugate comprises the VH domain and VL domain of an antibody selected from the group consisting of AF1856 (R&D Systems), MAB554 (R&D Systems), BF0174 (Affinity Biosciences), PAB31115 (Abnova Corporation), and CAL4 (Abcam). In some aspects, the binder is the heavy chain CDR1, CDR2 of the VH and VL sequences of antibodies selected from the group consisting of Kabat (cf. Kabat et al., (1991) Sequences of Proteins of Immunological Interest, NIH Publication No. 91-3242, Bethesda), Chothia (cf. exe., Chothia C & Lesk AM, (1987), J. MOL. BIOL. 196: 901-917), MacCallum (cf. MacCallum RM et al., (1996) J. MOL. BIOL. 262: 732-745), or AF1856 (R&D Systems), MAB554 (R&D Systems), BF0174 (Affinity Biosciences), PAB31115 (Abnova Corporation), and CAL4 (Abcam), determined according to any other CDR determination method known in the art, and Includes CDR3 and light chains CDR1, CDR2, and CDR3. Exemplary CD4 binders also include clonal ivalizumab, OKT4, RPA-T4, and S3.It may also be selected from antibodies or antibody fragments using the CDR of 5, SK3, N1UG0, RIV6, OTI18E3, MEM-241, B486A1, RFT-4g, 7E14, MDX.2, MEM-115, MEM-16, ICO-86, Edu-2, or ivalizumab.

[0223] An exemplary CD7 conjugate may be an antibody selected from the group consisting of MAB7579 (R&D Systems), AF7579 (R&D Systems), EPR22065 (Abcam), 1G10D8 (Proteintech), NBP2-32097 (Novus Biologicals), NBP2-38440 (Novus Biologicals), and antigen-binding fragments thereof. In some aspects, the conjugate comprises the VH domain and VL of an antibody selected from the group consisting of MAB7579 (R&D Systems), AF7579 (R&D Systems), EPR22065 (Abcam), 1G10D8 (Proteintech), NBP2-32097 (Novus Biologicals), and NBP2-38440 (Novus Biologicals). In some aspects, the conjugate is Kabat (Ref. Kabat et al ., (1991) Sequences of Proteins of Immunological Interest, NIH Publication No. 91-3242, Bethesda), Chothia (cf.: e.g., Chothia C & Lesk AM, (1987), J. MOL. BIOL. 196: 901-917), MacCallum (cf.: MacCallum RM et alIt comprises heavy chain CDR1, CDR2, and CDR3 and light chain CDR1, CDR2, and CDR3 of the VH and VL sequences of antibodies selected from the group consisting of MAB7579 (R&D Systems), AF7579 (R&D Systems), EPR22065 (Abcam), 1G10D8 (Proteintech), NBP2-32097 (Novus Biologicals), and NBP2-38440 (Novus Biologicals), determined according to any other CDR determination method known in the art, etc. Exemplary CD7 conjugates may also be selected from antibodies or antibody fragments utilizing the CDR of clone TH-69, 3Afl1, T3-3A1, 124-1D1, 3A1f, CD7-6B7, or VHH6.

[0224] An exemplary CD8 (CD8α, CD8α / α, CD8α / β or CD8β) binder may be an antibody selected from the group consisting of 2.43 (Invitrogen), Du CD8-1 (CD8α, Invitrogen), 9358-CD (CD8α / β, R&D Systems), MAB116 (CD8α, R&D Systems), ab4055 (CD8α, Abcam), C8 / 144B (CD8α, Novus Biologicals), YTS105.18 (CD8α, Novus Biologicals), TRX2 (US 2017-0198045 A1 or U.S. Patent No. 10,647768), and antigen-binding fragments thereof. In some aspects, the binder comprises the VH domain and VL domain of an antibody selected from the group consisting of 2.43 (Invitrogen), 51.1 (ATCC HB-230), Du CD8-1 (CD8α, Invitrogen), 9358-CD (CD8α / β, R&D Systems), MAB116 (CD8α, R&D Systems), ab4055 (CD8α, Abcam), C8 / 144B (CD8α, Novus Biologicals), and YTS105.18 (CD8α, Novus Biologicals). In some aspects, the binder is Kabat (cf. Kabat et al., (1991) Sequences of Proteins of Immunological Interest, NIH Publication No. 91-3242, Bethesda), Chothia (cf. exe., Chothia C & Lesk AM, (1987), J. MOL. BIOL. 196: 901-917), MacCallum (cf. MacCallum RM et al., (1996) J. MOL. BIOL. 262: 732-745), or determined according to any other CDR determination method known in the art, 2.It includes heavy chain CDR1, CDR2, and CDR3 and light chain CDR1, CDR2, and CDR3 of the VH and VL sequences of antibodies selected from the group consisting of 43 (Invitrogen), Du CD8- 1 (CD8α, Invitrogen), 9358-CD (CD8α / β, R&D Systems), MAB116 (CD8α, R&D Systems), ab4055 (CD8α, Abcam), C8 / 144B (CD8α, Novus Biologicals), and YTS105.18 (CD8α, Novus Biologicals). Exemplary CD8 conjugates may also be selected from antibodies or antibody fragments using the CDR of clones OKT-8, 51.1, S6F1, TRX2, and UCHT4, SP16, 3B5, C8-144B, HIT8a, RAVB3, LT8, 17D8, MEM-31, MEM-87, RIV11, DK-25, YTC141.1HL, or YTC182.20.

[0225] In some aspects, the cell targeter targets NK cells or NK cell populations. In some aspects, the NK cell targeter comprises one or more antibodies, antigen-binding fragments, or antigen-binding derivatives thereof that target NK cell surface antigens. Exemplary NK cell surface antigens include, but are not limited to, CD7, CD48, CD56, CD85a, CD85c, CD85d, CD85e, CD85f, CD85i, CD85j, CD158b2, CD161, CD244, CD16a, CD16b, IL-2 receptor, CD27, CD28, CD48, CD69, CD70, CD86, CD112, CD122, CD155, CD161, CD244, CD266, CD314 / NKG2D, CD336 / NKP44, CD337 / NKP30.

[0226] In some aspects, the immune cell targeter comprises a C-terminal cysteine ​​residue. In some aspects, the immune cell targeter comprises a Fab comprising cysteine ​​at the C-terminus of a heavy chain or light chain fragment. In some aspects, the Fab further comprises one or more amino acids between the heavy chain of the Fab and the C-terminal cysteine. For example, in some aspects, the Fab comprises two or more amino acids (e.g., partial hinge sequences) derived from an antibody hinge region between the C-terminus of the Fab and the C-terminal cysteine. In some aspects, the Fab comprises a heavy chain variable domain connected to an antibody CH1 domain and a light chain variable domain connected to an antibody light chain constant domain, wherein the CH1 domain and the light chain constant domain are connected by one or more interchain disulfide bonds, and the immune cell targeter further comprises a single chain variable fragment, e.g., a scFv connected to the C-terminus of the light chain constant domain by an amino acid linker.

[0227] In some aspects, the immune cell targeter comprises an immunoglobulin single variable domain, e.g., an immunoglobulin single variable domain (e.g., VHH). In some aspects, the immunoglobulin single variable domain comprises a cysteine ​​at the C-terminus. In some aspects, the immunoglobulin single variable domain further comprises a linker comprising one or more amino acids between the VHH domain and the C-terminal cysteine. In some aspects, the linker comprises one or more glycine residues, e.g., two glycine residues. In some aspects, the immune cell targeter comprises two or more VHH domains. In some aspects, two or more VHH domains are connected by an amino acid linker. In some aspects, the amino acid linker comprises one or more glycine and / or serine residues (e.g., one or more repeats of the sequence GGGGS). In some aspects, the immune cell targeter comprises a first VHH domain connected to an antibody CH1 domain and a second VHH domain connected to an antibody light chain constant domain, wherein the antibody CH1 domain and the antibody light chain constant domain are connected by one or more disulfide bonds (e.g., interchain disulfide bonds). In some aspects, the immune cell targeter comprises a VHH domain connected to an antibody CH1 domain, wherein the antibody CH1 domain is connected to an antibody light chain constant domain by one or more disulfide bonds.

[0228] Cell targeting device that targets hematopoietic stem cells

[0229] In some aspects, the target cell is a hematopoietic stem cell, and the cell targeting agent is an antibody or its antigen-binding fragment that binds to an antigen present on the hematopoietic stem cell.

[0230] In some aspects, the cell targeting site of the lipid nanoparticle binds to a hematopoietic stem cell surface molecule. In some aspects, the cell targeting site of the lipid nanoparticle is an antibody or a fragment thereof that binds to a hematopoietic stem cell surface molecule. In some aspects, the hematopoietic stem cell molecule is CD34, CD105 (also known as endoglin), or CD117 (also known as c-kit, tyrosine-protein kinase KIT, or obesity / stem cell growth factor receptor (SCFR)). In some aspects, the hematopoietic stem cell targeting site of the lipid nanoparticle is an antibody or a fragment thereof that binds to CD34, CD105, and / or CD117. In some aspects, the antibody is a human antibody or a humanized antibody. In some aspects, the antibody that binds to CD105 and / or CD117 is covalently coupled to a lipid within the lipid nanoparticle via a polyethylene glycol (PEG)-containing linker.

[0231] Lipid-cell targeting conjugate

[0232] In some aspects, the lipid nanoparticles described herein comprise one or more lipid-cell targeting conjugates. In some aspects, the lipid-cell targeting conjugate comprises a cell-targeting polypeptide or a fragment thereof, and a lipid. In some aspects, the cell targeter is covalently coupled to the lipid directly or through a linker. In some aspects, the cell targeter is covalently coupled to the lipid through a polyethylene glycol (PEG)-containing linker. In some aspects, the lipid-PEG-cell targeting conjugate is an insertable lipid-cell targeting conjugate of the lipid nanoparticles described herein.

[0233] In some aspects, the lipid linked to the cell targeting site via the PEG linker is distearoylglycerol (DSG), distearoyl-phosphatidylethanolamine (DSPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-glycero-phosphoglycerol (DSPG), dimyristoyl-glycerol (DMG), dipalmitoyl-phosphatidylethanolamine (DPPE), dipalmitoyl-glycerol (DPG), or ceramide.

[0234] In some aspects, the lipid-PEG-cell targeting conjugate comprises DSG-PEG, DSPE-PEG, DMPE-PEG, DSPG-PEG, DMG-PEG, DPPE-PEG, DPG-PEG, or ceramide-PEG. In some aspects, the lipid-PEG-cell targeting conjugate comprises DPG-PEG.

[0235] In some aspects, PEG within the lipid-PEG-cell targeting conjugate is PEG 1000, PEG 2000, PEG 2100, PEG 2200, PEG 2300, PEG 2400, PEG 2500, PEG 2600, PEG 2700, PEG 2800, PEG 2900, PEG 3000, PEG 3100, PEG 3200, PEG 3300, PEG 3400, PEG 3500, PEG 3600, PEG 3700, PEG 3800, PEG 3900, PEG 4000, PEG 4100, PEG 4200, PEG 4300, PEG 4400, PEG 4500, PEG 4600, PEG It is 4700, PEG 4800, PEG 4900, or PEG 5000. In some aspects, the PEG is PEG 2000 or PEG 3400. In some aspects, the PEG is PEG 2000 (PEG2K).

[0236] In some aspects, the lipid-cell targeting conjugate comprises a lipid-PEG2K antibody. In some aspects, the lipid-cell targeting conjugate comprises lipid-PEG2K-Fab. In some aspects, the lipid-cell targeting conjugate comprises lipid-PEG2K-scFv. In some aspects, the lipid-cell targeting conjugate comprises a lipid-PEG2K-immunoglobulin monovariable domain (ISV domain). In some aspects, the lipid nanoparticle comprises a lipid-cell targeting conjugate comprising a lipid-PEG2K antibody, a lipid-cell targeting conjugate comprising lipid-PEG2K-Fab, a lipid-cell targeting conjugate comprising lipid-PEG2K-scFv, and / or a lipid-cell targeting conjugate comprising a lipid-PEG2K-ISV domain.

[0237] In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG2K-cell targeting polypeptide or a fragment thereof. In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG2K-cell targeting antibody or a fragment thereof. In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG2K-cell targeting Fab. In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG2K-cell targeting scFv. In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG2K-cell targeting ISV domain. In some aspects, the lipid nanoparticle comprises a lipid-cell targeting conjugate comprising a DSPE-PEG2K antibody, a lipid-cell targeting conjugate comprising a DSPE-PEG2K-Fab, a lipid-cell targeting conjugate comprising a DSPE-PEG2K-scFv, and / or a lipid-cell targeting conjugate comprising a DSPE-PEG2K-ISV domain.

[0238] In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG3.4K-cell targeting polypeptide or a fragment thereof. In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG3.4K-cell targeting antibody or a fragment thereof. In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG3.4K-cell targeting Fab. In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG3.4K-cell targeting scFv. In some aspects, the lipid-cell targeting conjugate comprises a DSPE-PEG3.4K-cell targeting ISV domain. In some aspects, lipid nanoparticles comprise lipid-cell targeting conjugates comprising a DSPE-PEG3.4K antibody, lipid-cell targeting conjugates comprising DSPE-PEG3.4K-Fab, lipid-cell targeting conjugates comprising DSPE-PEG3.4K-scFv, and / or lipid-cell targeting conjugates comprising a DSPE-PEG3.4K-ISV domain.

[0239] In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-cell targeting polypeptide or a fragment thereof. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-cell targeting antibody or a fragment thereof. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-cell targeting Fab. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-cell targeting scFv. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-cell targeting ISV domain. In some aspects, the lipid nanoparticle comprises a lipid-cell targeting conjugate comprising a DPG-PEG2K antibody, a lipid-cell targeting conjugate comprising a DPG-PEG2K-Fab, a lipid-cell targeting conjugate comprising a DPG-PEG2K-scFv, and / or a lipid-cell targeting conjugate comprising a DPG-PEG2K-ISV domain.

[0240] In some aspects, the lipid of the lipid-cell targeting conjugate is conjugated to any position at the N-terminus, C-terminus, or intermediate portion of the cell targeting polypeptide or its fragment. In some aspects, the cell targeting polypeptide is an antibody, Fab, scFv, or immunoglobulin monovariable domain, and the lipid is conjugated to the N-terminus of the cell targeting antibody, Fab, scFv, or immunoglobulin monovariable domain. In some aspects, the lipid is conjugated to the C-terminus of the cell targeting antibody, Fab, scFv, or immunoglobulin monovariable domain. In some aspects, the lipid is conjugated to a position between the N-terminus and C-terminus of the cell targeting antibody, Fab, scFv, or immunoglobulin monovariable domain. In some aspects, the lipid of the lipid-cell targeting conjugate is conjugated to the cell targeting polypeptide or its fragment via maleimide-thiol chemistry.

[0241] In some aspects, the lipid nanoparticle comprises a plurality of lipid-cell targeting conjugates. In some aspects, the plurality of lipid-cell targeting conjugates are covalently bonded to different PEG linkers. In some aspects, the plurality of lipid-cell targeting conjugates are presented on the surface of the lipid nanoparticle, and each targeting conjugate binds to a different molecule or part of a molecule on the target cell. In some aspects, the plurality of lipid-cell targeting conjugates each bind to a different epitope on the same antigen. In some aspects, the plurality of lipid-cell targeting conjugates each bind to a different epitope on a different antigen. Advantageously, lipid nanoparticles having a plurality of lipid-cell targeting conjugates on their surface increase the binding strength and specificity of targeting interactions for specific target cells.

[0242] In some aspects, the lipid nanoparticles comprise a lipid-PEG2K-CD3 targeter. In some aspects, the lipid nanoparticles comprise a lipid-PEG2K-CD4 targeter. In some aspects, the lipid nanoparticles comprise a lipid-PEG2K-CD8 targeter. In some aspects, the lipid nanoparticles comprise a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD3 targeter, a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD4 targeter, and / or a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD8 targeter.

[0243] In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD3 targeter. In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD4 targeter. In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD8 targeter. In some aspects, the lipid nanoparticles comprise a lipid-cell targeter conjugate comprising a DPG-PEG2K-CD3 targeter, a lipid-cell targeter conjugate comprising a DPG-PEG2K-CD4 targeter, and / or a lipid-cell targeter conjugate comprising a DPG-PEG2K-CD8 targeter.

[0244] In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-CD3 antibody. In some aspects, the lipid-cell targeting conjugate comprises DPG-PEG2K-CD3 Fab. In some aspects, the lipid-cell targeting conjugate comprises DPG-PEG2K-CD3 scFv. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-CD3 immunoglobulin monovariable domain.

[0245] In some aspects, lipid nanoparticles comprise a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD3 antibody, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD3 Fab, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD3 scFv, and / or a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD3 immunoglobulin monovariable domain.

[0246] In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-CD4 antibody. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-CD4 Fab. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-CD4 scFv. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-CD4 immunoglobulin monovariable domain.

[0247] In some aspects, lipid nanoparticles comprise a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD4 antibody, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD4 Fab, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD4 scFv, and / or a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD4 immunoglobulin monovariable domain.

[0248] In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-CD8 antibody. In some aspects, the lipid-cell targeting conjugate comprises DPG-PEG2K-CD8 Fab. In some aspects, the lipid-cell targeting conjugate comprises DPG-PEG2K-CD8 scFv. In some aspects, the lipid-cell targeting conjugate comprises a DPG-PEG2K-CD8 immunoglobulin monovariable domain.

[0249] In some aspects, lipid nanoparticles comprise a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD8 antibody, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD8 Fab, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD8 scFv, and / or a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD8 immunoglobulin monovariable domain.

[0250] In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD3 antibody, a DPG-PEG2K-CD4 antibody, and / or a DPG-PEG2K-CD8 antibody. In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD3 Fab, a DPG-PEG2K-CD4 Fab, and / or a DPG-PEG2K-CD8 Fab. In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD3 scFv, a DPG-PEG2K-CD4 scFv, and / or a DPG-PEG2K-CD8 scFv. In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD3 immunoglobulin monovariable domain, a DPG-PEG2K-CD4 immunoglobulin monovariable domain, and / or a DPG-PEG2K-CD8 immunoglobulin monovariable domain.

[0251] In some aspects, lipid nanoparticles comprise a DPG-PEG2K-CD3 antibody, DPG-PEG2K-CD3 Fab, DPG-PEG2K-CD3 scFv, DPG-PEG2K-CD3 immunoglobulin monovariable domain, DPG-PEG2K-CD4 antibody, DPG-PEG2K-CD4 Fab, DPG-PEG2K-CD4 scFv, DPG-PEG2K-CD4 immunoglobulin monovariable domain, DPG-PEG2K-CD8 antibody, DPG-PEG2K-CD8 Fab, DPG-PEG2K-CD8 scFv, or DPG-PEG2K-CD8 immunoglobulin monovariable domain, or any combination thereof.

[0252] In some aspects, the lipid nanoparticles comprise a lipid-PEG2K-CD56 targeter. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD56 antibody. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD56 Fab. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD56 scFv. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD56 immunoglobulin monovariable domain.

[0253] In some aspects, the lipid nanoparticles contain a DPG-PEG2K-CD56 targeter. In some aspects, the lipid-cell targeter conjugate contains a DPG-PEG2K-CD56 antibody. In some aspects, the lipid-cell targeter conjugate contains a DPG-PEG2K-CD56 Fab. In some aspects, the lipid-cell targeter conjugate contains a DPG-PEG2K-CD56 scFv. In some aspects, the lipid-cell targeter conjugate contains a DPG-PEG2K-CD56 immunoglobulin monovariable domain.

[0254] In some aspects, the lipid nanoparticle comprises a lipid-PEG2K-CD105 targeter. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD105 antibody. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD105 Fab. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD105 scFv. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD105 immunoglobulin monovariable domain. In some aspects, the lipid nanoparticle comprises a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD105 antibody, a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD105 Fab, a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD105 scFv, and / or a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD105 immunoglobulin monovariable domain.

[0255] In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD105 targeter. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD105 antibody. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD105 Fab. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD105 scFv. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD105 immunoglobulin monovariable domain. In some aspects, lipid nanoparticles comprise a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD105 antibody, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD105 Fab, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD105 scFv, and / or a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD105 immunoglobulin monovariable domain.

[0256] In some aspects, the lipid nanoparticle comprises a lipid-PEG-CD117 targeter. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD117 antibody. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD117 Fab. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD117 scFv. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD117 immunoglobulin monovariable domain. In some aspects, the lipid nanoparticle comprises a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD117 antibody, a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD117 Fab, a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD117 scFv, and / or a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD117 immunoglobulin monovariable domain.

[0257] In some aspects, the lipid nanoparticles comprise a DPG-PEG-CD117 targeter. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD117 antibody. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD117 Fab. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD117 scFv. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD117 immunoglobulin monovariable domain. In some aspects, lipid nanoparticles comprise a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD117 antibody, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD117 Fab, a lipid-cell targeting conjugate comprising DPG-PEG2K-CD117 scFv, and / or a lipid-cell targeting conjugate comprising a DPG-PEG2K-CD117 immunoglobulin monovariable domain.

[0258] In some aspects, the lipid nanoparticle comprises a lipid-PEG2K-CD34 targeter. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD34 antibody. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD34 Fab. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD34 scFv. In some aspects, the lipid-cell targeter conjugate comprises a lipid-PEG2K-CD34 immunoglobulin monovariable domain. In some aspects, the lipid nanoparticle comprises a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD34 antibody, a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD34 Fab, a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD34 scFv, and / or a lipid-cell targeter conjugate comprising a lipid-PEG2K-CD34 immunoglobulin monovariable domain.

[0259] In some aspects, the lipid nanoparticle comprises a DPG-PEG2K-CD34 targeter. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD34 antibody. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD34 Fab. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD34 scFv. In some aspects, the lipid-cell targeter conjugate comprises a DPG-PEG2K-CD34 immunoglobulin monovariable domain. In some aspects, the lipid nanoparticle comprises a lipid-cell targeter conjugate comprising a DPG-PEG2K-CD34 antibody, a lipid-cell targeter conjugate comprising a DPG-PEG2K-CD34 Fab, a lipid-cell targeter conjugate comprising a DPG-PEG2K-CD34 scFv, and / or a lipid-cell targeter conjugate comprising a DPG-PEG2K-CD34 immunoglobulin monovariable domain.

[0260] In some aspects, the lipid nanoparticles comprise a lipid-PEG2K-CD105 targeter, a lipid-DPG-PEG2K-CD117 targeter, and / or a lipid-PEG2K-CD34 targeter. In some aspects, the lipid nanoparticles comprise a DPG-PEG2K-CD105 targeter, a DPG-PEG2K-CD117 targeter, and / or a DPG-PEG2K-CD34 targeter.

[0261] In some aspects, lipid nanoparticles comprise a DPG-PEG2K-CD105 antibody, DPG-PEG2K-CD105 Fab, DPG-PEG2K-CD105 scFv, DPG-PEG2K-CD105 immunoglobulin monovariable domain, a DPG-PEG2K-CD117 antibody, DPG-PEG2K-CD117 Fab, DPG-PEG2K-CD117 scFv, DPG-PEG2K-CD117 immunoglobulin monovariable domain, a DPG-PEG2K-CD34 antibody, DPG-PEG2K-CD34 Fab, DPG-PEG2K-CD34 scFv, or a DPG-PEG2K-CD34 immunoglobulin monovariable domain, or any combination thereof.

[0262] In some aspects, the lipid-cell targeting conjugate of lipid nanoparticles comprises about 1 g to about 50 g of cell targeting groups per mole of lipid. In some aspects, the lipid-cell targeting conjugate of lipid nanoparticles comprises about 10 g to about 20 g of cell targeting groups per mole of lipid. In some aspects, the lipid-antibody conjugate of lipid nanoparticles comprises about 12 g of cell targeting groups per mole of lipid.

[0263] In some aspects, the lipid-cell targeting conjugate comprises about 1 g to about 10 g of cell targeting per mole of lipid. In some aspects, the lipid-cell targeting conjugate comprises about 2 g to about 9 g of cell targeting per mole of lipid. In some aspects, the lipid-cell targeting conjugate comprises about 3 g to about 9 g of cell targeting per mole of lipid.

[0264] In some aspects, the lipid-antibody conjugate contains about 1 g to about 10 g of antibodies per mole of lipid. In some aspects, the lipid-antibody conjugate contains about 2 g to about 9 g of antibodies per mole of lipid. In some aspects, the lipid-antibody conjugate contains about 3 g to about 9 g of antibodies per mole of lipid.

[0265] In some aspects, the lipid-Fab conjugate contains about 1 g to about 10 g of Fab per mole of lipid. In some aspects, the lipid-Fab conjugate contains about 2 g to about 9 g of Fab per mole of lipid. In some aspects, the lipid-Fab conjugate contains about 3 g to about 9 g of Fab per mole of lipid.

[0266] In some aspects, the lipid-scFv conjugate contains about 1 g to about 10 g of scFv per mole of lipid. In some aspects, the lipid-scFv conjugate contains about 2 g to about 9 g of scFv per mole of lipid. In some aspects, the lipid-scFv conjugate contains about 3 g to about 9 g of scFv per mole of lipid.

[0267] In some aspects, the lipid-immunoglobulin single variable domain conjugate comprises about 1 g to about 10 g of ISV domains per mole of lipid. In some aspects, the lipid-ISV domain conjugate comprises about 2 g to about 9 g of ISV domains per mole of lipid. In some aspects, the lipid-ISV domain conjugate comprises about 3 g to about 9 g of ISV domains per mole of lipid.

[0268] In some aspects, the lipid-cell targeting conjugate is present in the lipid nanoparticles in a range of about 0.001 mol% to about 0.5 mol%. In some aspects, the lipid-cell targeting conjugate is present in the lipid nanoparticles in a range of about 0.002 mol% to about 0.2 mol%. In some aspects, the lipid-cell targeting conjugate is present in the lipid nanoparticles in a range of about 0.001 mol% to about 0.4 mol%; about 0.001 mol% to about 0.3 mol%; about 0.001 mol% to about 0.2 mol%; about 0.001 mol% to about 0.1 mol%; or about 0.001 mol% to about 0.08 mol%; about 0.001 mol% to about 0.06 mol%; about 0.001 mol% to about 0.04 mol%; about 0.001 mol% to about 0.02 mol%; Or it is present in the range of about 0.001 mol% to about 0.01 mol%. In some aspects, the lipid-cell targeting conjugate is present in lipid nanoparticles in an amount of about 0.002 mol% to about 0.5 mol%; about 0.003 mol% to about 0.5 mol%; about 0.004 mol% to about 0.5 mol%; about 0.005 mol% to about 0.5 mol%; about 0.006 mol% to about 0.5 mol%; about 0.008 mol% to about 0.5 mol%; about 0.01 mol% to about 0.5 mol%; about 0.02 mol% to about 0.5 mol%; about 0.03 mol% to about 0.5 mol%; about 0.04 mol% to about 0.5 mol%; about 0.05 mol% to about 0.5 mol%; About 0.06 mol% to about 0.5 mol%; about 0.07 mol% to about 0.5 mol%; about 0.08 mol% to about 0.5 mol%; about 0.09 mol% to about 0.5 mol%; about 0.1 mol% to about 0.5 mol%; about 0.15 mol% to about 0.5 mol%; about 0.2 mol% to about 0.5 mol%; about 0.It exists in the range of 25 mol% to about 0.5 mol%; about 0.3 mol% to about 0.5 mol%; about 0.35 mol% to about 0.5 mol%; or about 0.4 mol% to about 0.5 mol%.

[0269] In some aspects, the lipid-cell targeting conjugate containing lipid nanoparticles further includes free PEG lipids to reduce the amount of non-specific binding through the targeter. In some aspects, the free PEG lipids may be the same as or different from the PEG lipids included in the conjugate. In some aspects, free PEG lipids are PEG-distearoyl-phosphatidylethanolamine (PEG-DSPE) or PEG-dimyristoyl-phosphatidylethanolamine (PEG-DMPE), N-(methylpolyoxyethylene oxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE-PEG), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (PEG-DMG), 1,2-dipalmitoyl-rac-glycero-3-methylpolyoxyethylene (PEG-DPG), 1,2-dioleoyl-rac-glycerol, methoxypolyethylene glycol (DOG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (PEG-DSG), N-palmitoyl-sphingosine-1-succinyl[methoxy(polyethylene Selected from the group consisting of glycol](PEG-ceramide), DSPE-PEG-cysteine, or derivatives thereof, all of which have an average PEG length between 2000 and 5000, or a PEG length of about 2000, 3400, or 5000. In some aspects, lipid nanoparticles comprise a mixture of two or more PEGylated lipids.

[0270] Cargo

[0271] In some aspects, lipid nanoparticles comprise nucleic acid molecules placed on the lipid nanoparticles to deliver cargo, for example, to the cells (e.g., immune cells or hematopoietic stem cells) or tissues of a target.

[0272] In some aspects, lipid nanoparticles comprise nucleic acids, e.g., DNA or RNA, e.g., mRNA, tRNA, microRNA, siRNA, gRNA (guide RNA), circRNA (circular RNA), ribozymes, decoy RNA, or Dicer substrate siRNA. In some aspects, the nucleic acid comprises naturally occurring components such as naturally occurring bases, sugars, or linkers (e.g., phosphodiester linkers). In some aspects, the nucleic acid comprises non-naturally occurring components or modifications (e.g., thioester linkers). For example, the nucleic acid may be synthesized to contain bases, sugars, or linker modifications known to those skilled in the art. Additionally, the nucleic acid may be linear or circular, or may have any desired configuration. In some aspects, lipid nanoparticles comprise a plurality of nucleic acid molecules, e.g., a plurality of RNA molecules that may be identical or different.

[0273] In some aspects, one or more lipid nanoparticle compositions comprising one or more different mRNAs are combined and / or simultaneously contacted with a cell. In some aspects, the mRNA may comprise one or more of a stem loop, a chain-terminating nucleoside, a poly-A sequence, a polyadenylation signal, and / or a 5' cap structure. In some aspects, the mRNA may encode a receptor such as a chimeric antigen receptor (CAR) for the transfection of immune cells. In some aspects, the mRNA may encode a Cas nuclease. In some aspects, the RNA may comprise a guide RNA.

[0274] In some aspects, the wt / wt ratio of lipid components to carbohydrates (e.g., mRNA) in lipid nanoparticles is about 1:1 to about 50:1, e.g., 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, or 50:1. In some aspects, the wt / wt ratio of lipid components to carbohydrates in lipid nanoparticles is about 5:1 to about 50:1. In some aspects, the wt / wt ratio of lipid components to carbohydrates in lipid nanoparticles is about 5:1 to about 40:1. In some aspects, the wt / wt ratio of lipid components to cargo in lipid nanoparticles is about 10:1 to about 40:1. In some aspects, the wt / wt ratio of lipid components to cargo in lipid nanoparticles is about 15:1 to about 25:1.

[0275] In some aspects, the encapsulation efficiency of the cargo (e.g., mRNA) within the lipid nanoparticles is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or 99%.

[0276] In some aspects, the lipid nanoparticles described herein contain less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 7.5%, less than 5%, less than 2.5%, or less than 1% of dye-accessible RNA.

[0277] In some aspects, one or more mRNAs and lipids are selected to provide a specific N:P ratio (ratio of a positively charged lipid or polymeric amine (N = nitrogen) group to a negatively charged nucleic acid phosphate (P) group). The N:P ratio of the lipid nanoparticle composition refers to the molar ratio of the number of nitrogen atoms in one or more lipids to the number of phosphate groups in the mRNA. Generally, a lower N:P ratio is preferred. The N:P ratio may depend on the specific lipid and its pKa. In some aspects, the mRNA and lipids and / or their relative amounts within the lipid nanoparticles are selected to provide an N:P ratio of about 1:1 to about 30:1, or about 1:1 to about 20:1. In some aspects, the N:P ratio is, for example, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, or 8:1. In certain aspects, the N:P ratio is about 2:1 to about 5:1. In some aspects, the N:P ratio is about 4:1. In some aspects, the N:P ratio is about 4:1 to about 8:1. In some aspects, the N:P ratio may be about 4:1, about 4.5:1, about 4.6:1, about 4.7:1, about 4.8:1, about 4.9:1, about 5.0:1, about 5.1:1, about 5.2:1, about 5.3:1, about 5.4:1, about 5.5:1, about 5.6:1, about 5.7:1, about 6.0:1, about 6.5:1, or about 7.0:1.

[0278] composition

[0279] The present invention provides compositions comprising lipid nanoparticles as described herein. In some aspects, the compositions provided herein comprise lipid nanoparticles comprising ionizable lipids. In some aspects, the ionizable lipid of the lipid nanoparticles comprises a structure of Formula I or a salt thereof:

[0280] [Chemical Formula I]

[0281]

[0282] (Here,

[0283] R 1 , R 2 , and R 3 Each is independently combined or C 1-3 It is an alkylene;

[0284] R 1A , R 2A , and R 3A Each is independently bonded to a C1-10 alkylene;

[0285] R 1A1 , R 1A2 , R 1A3 , R 2A1 , R 2A2 , R 2A3 , R 3A1 , R 3A2 , and R 3A3 H and C are independently 1-20 Alkyl, C 1-20 Alkenyl, -(CH2) 0-10 C(O)OR a1 , or -(CH2) 0-10 OC(O)R a2 and; R a1 and R a2 C each independently 1-2 alkyl or C 1-2 It is alkenyl; R 3B Is

[0286]

[0287] And,

[0288] R 3B1 C 1-6 It is an alkylene;

[0289] R 3B2 and R 3B3 Each independently H or C 1-6 It is an alkyl).

[0290] In some aspects, the ionizable lipid of the lipid nanoparticle comprises the structure of Formula II (Lipid 15):

[0291] [Chemical Formula II]

[0292] .

[0293] In some aspects, the ionizable lipid of the lipid nanoparticles comprises the structure of Formula III (KC2):

[0294] [Chemical Formula III]

[0295] .

[0296] In some aspects, the ionizable lipid of the lipid nanoparticles comprises the structure of formula IV (KC3):

[0297] [Chemical Formula IV]

[0298] .

[0299] In some aspects, the ionizable lipid of the lipid nanoparticle comprises the structure of formula V:

[0300] [Chemical Formula V]

[0301]

[0302] (Here, R 1 and R 2 Each is independently a lipid).

[0303] In some aspects, the ionizable lipid comprises the structure of formula VI:

[0304] [Chemical Formula VI]

[0305]

[0306] (Here, R 1 and R 2 Each is independently a lipid).

[0307] In some embodiments, if the ionizable lipid of the lipid nanoparticle comprises a structure of Formula V or Formula VI, R 1 and R 2 Each is independently a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkenyl. In some embodiments, where the ionizable lipid of the lipid nanoparticle comprises a structure of Formula V or Formula VI, R 1 and R 2is the same lipid. In some embodiments, if the ionizable lipid of the lipid nanoparticle comprises a structure of Formula V or Formula VI, R 1 and R 2 is a different lipid. In some embodiments, the lipid is a hydrocarbon (e.g., substituted or unsubstituted, saturated or unsaturated, branched or unbranched hydrocarbon). The hydrocarbon may be an alkane, an alkene, or an alkyne. In some embodiments, the hydrocarbon chain is saturated or unsaturated. In certain embodiments, the unsaturated hydrocarbon chain comprises at least one, at least two, at least three, at least four, at least five, or at least six carbon-carbon double bonds (e.g., cis double bonds and / or trans double bonds). In some embodiments, the lipid is a substituted or unsubstituted C 7-36 It is an alkyl. In certain embodiments, the lipid is a substituted or unsubstituted C 7-36 It is an alkenyl. In certain embodiments, the lipid is an unsubstituted C 7-36 Alkyl or unsubstituted C 7-36 It is an alkenyl. In certain embodiments, the hydrocarbon is substituted with alkyl, alkenyl, alkynyl, amino, alkylamino, dialkylamino, trialkylamino, hydroxyl, alkoxy, carbonyl, halogen, aryl, heterocyclic, aromatic heterocyclic, cyano, amide, carbamoyl, carboxylic acid, ester, thioether, alkylthioether, thiol, ureido, or a combination thereof. Each of these groups may be substituted again. In some embodiments, the hydrocarbon is substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, or more than 10 substituents.

[0308] In some aspects, the lipid nanoparticles of the composition further comprise an auxiliary lipid, a structural lipid, a PEG lipid, and optionally a Cargo. In some aspects, the lipid nanoparticles of the composition further comprise the lipid-cell targeting conjugate described herein.

[0309] In some aspects, the lipid nanoparticle composition comprises one or more pharmaceutically acceptable excipients. In some aspects, the lipid nanoparticle composition comprises one or more solvents, one or more salts, and / or one or more sugars or other cryoprotectants. In some aspects, conventional excipients and auxiliary components are used in the pharmaceutical composition, except where any conventional excipient or auxiliary component may be incompatible with one or more components of the lipid nanoparticle composition described herein. For example, said excipient or auxiliary component may be incompatible with said component if the combination of an excipient or auxiliary component and a component of the lipid nanoparticle composition may result in any undesirable biological effect or other harmful effect.

[0310] In some aspects, one or more excipients may constitute more than 50% of the total mass or volume of the pharmaceutical composition containing lipid nanoparticles. For example, one or more excipients may constitute 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the pharmaceutical composition.

[0311] method

[0312] Method for manufacturing lipid nanoparticles

[0313] In some aspects, lipid nanoparticles are prepared using rapid mixing via an orbital vortexer, a T-mixer, or microfluidic mixing. Orbital vortexer mixing is performed by vortexing at 2,500 rpm immediately after rapidly adding a lipid solution in ethanol to an aqueous solution of nucleic acid. In some aspects, lipid nanoparticles are prepared using a microfluidic mixing step. In some aspects, microfluidic mixing is achieved by mixing an aqueous stream and an organic stream at a controlled flow rate in a microfluidic channel, for example, using a microfluidic chip (Precision Nanosystems, Vancouver, BC) featuring a NanoAssemblr device and an optimized mixing chamber geometry. In some aspects, lipid nanoparticles are encapsulated by rapidly mixing an ethanolic lipid solution and an aqueous nucleic acid solution using a microfluidic mixing step, resulting in the encapsulation of nucleic acid within solid lipid nanoparticles. Subsequently, the nanoparticle suspension is buffered with an all-aqueous buffer using a membrane filtration device selected for ethanol removal and nanoparticle maturation.

[0314] How to use

[0315] The present disclosure provides a method for delivering a Cargo to a target cell or tissue, for example, to a target cell or tissue of a subject, and lipid nanoparticles or a pharmaceutical composition containing lipid nanoparticles for use in such a method. Any disclosure of the present invention, for example, a method for treating a disease or disorder, for example, a method for delivering nucleic acids to a cell, or for example, a method for generating a polypeptide of interest in a cell, should also be interpreted as a disclosure of lipid nanoparticles or a pharmaceutical composition containing said lipid nanoparticles for use in such a method.

[0316] In some aspects, a method for generating a polypeptide of interest in target cells is provided, and lipid nanoparticles or a pharmaceutical composition containing lipid nanoparticles for use in such a method is provided. The method for generating a polypeptide in such cells comprises bringing the cells into contact with lipid nanoparticles containing, for example, a nucleic acid of interest. When the cells are brought into contact with lipid nanoparticles, the nucleic acid may be absorbed by the cells and translated to generate the polypeptide of interest.

[0317] In some aspects, the step of contacting cells with a lipid nanoparticle composition containing, for example, mRNA encoding a polypeptide of interest, may be performed in vivo, in vitro, or in vitro. The amount of the lipid nanoparticle composition contacted with the cells, and / or the amount of mRNA therein, may vary depending on the type of cell or tissue contacted, the means of administration, the physicochemical properties of the lipid nanoparticles and the mRNA therein (e.g., size, charge, and chemical composition), and other factors.

[0318] In some aspects, the step of contacting lipid nanoparticles containing cargo with a cell involves or induces transfection in which the lipid nanoparticles fuse with the cell membrane to allow cargo to be delivered into the cell. Upon introduction into the cytoplasm of the cell, cargo, e.g., mRNA, is subsequently translated into a protein or peptide through the protein synthesis machinery within the cytoplasm of the cell.

[0319] In some aspects, polypeptide production efficiency in cells can be determined, and cells can be repeatedly re-contacted with lipid nanoparticles until the desired target polypeptide production efficiency is achieved.

[0320] In some aspects, a method is provided for delivering a cargo, for example, nucleic acid, to mammalian cells or tissues, for example, to mammalian cells or tissues of a subject. In some aspects, delivering the nucleic acid to such cells or tissues comprises administering the lipid nanoparticle composition described herein to a subject, for example, by injecting it into the subject.

[0321] In some aspects, after administration, lipid nanoparticles may target and / or come into contact with the target's cells, e.g., immune cells or hematopoietic stem cells. When cells are brought into contact with the lipid nanoparticle composition, nucleic acids, e.g., translatable mRNA, may be translated within the cell to produce the polypeptide of interest.

[0322] In some aspects, the lipid nanoparticles described herein provide at least one of the following advantages:

[0323] a. Increased specificity of targeted delivery to target cells compared to reference lipid nanoparticles;

[0324] b. Increase in the half-life of nucleic acids or polypeptides encoded by nucleic acids in target cells compared to reference lipid nanoparticles;

[0325] c. Increase in transfection rate compared to reference lipid nanoparticles; and / or

[0326] d. High nucleic acid encapsulation efficiency.

[0327] In some embodiments, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% or less of non-target cells are transfected by the lipid nanoparticles described herein. For example, in some embodiments, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% or less of unwanted immune cells not intended to be the destination of delivery are transfected by lipid nanoparticles. In some embodiments, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% or less of unwanted hematopoietic stem cells not intended to be the destination of delivery are transfected by lipid nanoparticles.

[0328] In some aspects, the half-life of the nucleic acid delivered to a target cell, e.g., an immune cell or a hematopoietic stem cell, by the lipid nanoparticles described herein, or the half-life of the polypeptide encoded by the nucleic acid delivered by the lipid nanoparticles, is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, or more longer than the half-life of the nucleic acid delivered to the target cell by a reference lipid nanoparticle or the half-life of the polypeptide encoded by the nucleic acid delivered by the reference lipid nanoparticles.

[0329] In some aspects, the composition of the lipid nanoparticles differs from the composition of the reference lipid nanoparticles in the type of ionizable cationic lipid, the relative amount of ionizable cationic lipid, the type of PEG lipid, the relative amount of PEG lipid, the type of auxiliary lipid, the relative amount of auxiliary lipid, the type of structural lipid, the relative amount of structural lipid, the type of Cargo or cell targeting agent, or any combination thereof. In some aspects, the reference lipid nanoparticles are lipid nanoparticles containing auxiliary lipids in a range of less than 20 mol%. In some aspects, the reference lipid nanoparticles are lipid nanoparticles containing auxiliary lipids in a range of less than 16 mol%. In some aspects, the reference lipid nanoparticles are lipid nanoparticles containing auxiliary lipids in a range of about 10 mol% to about 15 mol%. In some aspects, the reference lipid nanoparticles are lipid nanoparticles containing auxiliary lipids in a range of more than 50 mol%.

[0330] In some aspects, the composition of the lipid nanoparticles differs from the composition of the reference lipid nanoparticles only in the type of ionizable cationic lipid. In some aspects, the composition of the lipid nanoparticles differs from the composition of the reference lipid nanoparticles in the relative amount of ionizable cationic lipid. In some aspects, the composition of the lipid nanoparticles differs from the composition of the reference lipid nanoparticles only in the type of auxiliary lipid. In some aspects, the composition of the lipid nanoparticles differs from the composition of the reference lipid nanoparticles in the relative amount of auxiliary lipid. In some aspects, the composition of the lipid nanoparticles differs from the composition of the reference lipid nanoparticles in the relative amount of auxiliary lipid, wherein the lipid nanoparticles contain about 16 mol% to about 20 mol% of auxiliary lipid, while the reference lipid nanoparticles contain about 10 mol% to about 15 mol% of auxiliary lipid, and the difference in total lipid content is compensated by changing the amount of structural lipid within the lipid nanoparticles; otherwise, the lipid nanoparticles and the reference lipid nanoparticles are identical.

[0331] In some aspects, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more of the target cells intended to be the destination of delivery are transfected by lipid nanoparticles.

[0332] In some aspects, the expression level of nucleic acid in target cells delivered by the lipid nanoparticles described herein is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 15 times, 20 times or more higher than the expression level of nucleic acid in the same target cells delivered by reference lipid nanoparticles.

[0333] In some aspects, specific delivery using the lipid nanoparticles described herein may result in an increase of more than 2, 5, 10, 15, or 20 times in the amount of cargo delivered to a targeted destination compared to other destinations (e.g., non-target cells).

[0334] In some aspects, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more of immune target cells are transfected by lipid nanoparticles.

[0335] In some aspects, the expression level of nucleic acids in immune target cells delivered by the lipid nanoparticles described herein is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 15 times, 20 times or more higher than the expression level of nucleic acids in immune target cells delivered by reference lipid nanoparticles.

[0336] In some aspects, specific delivery using the lipid nanoparticles described herein may result in an increase exceeding 2, 5, 10, 15, or 20 times in the amount of cargo delivered to immune target cells compared to immune non-target cells or other non-target cells.

[0337] In some aspects, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more of hematopoietic stem cell target cells are transfected by lipid nanoparticles.

[0338] In some aspects, the expression level of nucleic acids in hematopoietic stem cells delivered by the lipid nanoparticles described herein is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 15 times, 20 times or more higher than the expression level of nucleic acids in the same hematopoietic stem cells delivered by reference lipid nanoparticles.

[0339] In some aspects, specific delivery using lipid nanoparticles described herein may result in an increase of more than 2, 5, 10, 15, or 20 times in the amount of cargo delivered to hematopoietic stem target cells compared to hematopoietic non-target cells or other non-target cells.

[0340] In some aspects, the lipid nanoparticle compositions described herein may be useful for treating diseases, disorders, or pathological conditions characterized by a missing or abnormal polypeptide or polypeptide activity. In some aspects, when lipid nanoparticles comprising a nucleic acid encoding a missing or abnormal polypeptide, e.g., mRNA, are delivered to a cell, the polypeptide may be generated by the translation of the mRNA, thereby reducing or eliminating problems caused by the absence of the polypeptide or abnormal activity caused by the polypeptide.

[0341] In some aspects, a method for targeting nucleic acid delivery to immune cells of a subject is provided herein. In some aspects, the method comprises contacting immune cells with lipid nanoparticles described herein. In some aspects, the method comprises contacting immune cells with lipid nanoparticles in vitro. In some aspects, the method comprises contacting immune cells with lipid nanoparticles in vitro. In some aspects, the method comprises contacting immune cells with lipid nanoparticles in vivo.

[0342] In some aspects, a method for regulating the cellular function of immune cells of a subject is provided. In some aspects, the method comprises administering lipid nanoparticles to a subject. In some aspects, the lipid nanoparticles comprise immune cell targeting groups.

[0343] In some aspects, the immune cell targeter is the CD3 targeter, CD4 targeter, CD7 targeter, or CD8 targeter.

[0344] In some aspects, the regulation of cell function involves reprogramming immune cells to initiate an immune response. In some aspects, the regulation of cell function involves expressing a chimeric antigen receptor (CAR) in immune cells. In some aspects, the regulation of cell function involves contacting T cells with lipid nanoparticles containing RNA encoding a CAR. In some aspects, the lipid nanoparticles further comprise T cell targeters, e.g., CD3 targeters, CD4 targeters, and / or CD8 targeters. In some aspects, the regulation of cell function involves increasing cytotoxic activity in CD8+ T cells, wherein the lipid nanoparticles used for contact with said T cells contain a CD8 targeter, and the nucleic acid placed on said lipid nanoparticles encodes a CAR.

[0345] In some aspects, the regulation of cell function involves delivering nucleic acids encoding gene editing systems (e.g., site-specific nucleases and, optionally, guide RNA) to T cells.

[0346] In some aspects, the immune cell targeting site is CD56. In some aspects, the regulation of cell function involves reprogramming NK cells to initiate an immune response. In some aspects, the regulation of cell function involves expressing CARs in NK cells. In some aspects, the regulation of cell function involves increasing cytotoxic activity in NK cells.

[0347] In some aspects, the regulation of cell function involves delivering nucleic acids encoding gene editing systems (e.g., site-targeting nucleases and, optionally, guide RNA) to NK cells.

[0348] In some aspects, a method for targeting the delivery of nucleic acids to hematopoietic stem cells of a subject is provided herein. In some aspects, the method comprises contacting hematopoietic stem cells with lipid nanoparticles described herein. In some aspects, the method comprises contacting hematopoietic stem cells with lipid nanoparticles in vitro. In some aspects, the method comprises contacting hematopoietic stem cells with lipid nanoparticles in vitro. In some aspects, the method comprises contacting hematopoietic stem cells with lipid nanoparticles in vivo.

[0349] In some aspects, lipid nanoparticles contain hematopoietic stem cell targeting sites. In some aspects, the hematopoietic stem cell targeting site is a CD105 targeting site, a CD117 targeting site, or a CD34 targeting site.

[0350] In some aspects, the lipid nanoparticles provided herein are delivered to a subject having a disease for in vivo gene editing and treatment of the disease. In some aspects, the lipid nanoparticles are delivered to a subject having hemoglobinopathy. In some aspects, a method for treating α-hemoglobinopathy is provided. In some aspects, a method for treating β-hemoglobinopathy is provided. In some aspects, β-hemoglobinopathy is β-thalassemia. In some aspects, β-hemoglobinopathy is sickle cell disease.

[0351] In some aspects, the lipid nanoparticles described herein are delivered to subjects having sickle cell disease or beta-thalassemia for in vivo gene editing and treatment of the subjects. In some aspects, the lipid nanoparticles comprise one or more nucleic acids encoding a gene editing system that targets a locus where an increase in hemoglobin F (HbF) in the subjects' cells is caused by gene editing for the treatment of the disease (e.g., sickle cell disease and beta-thalassemia).

[0352] In some aspects, lipid nanoparticles delivered to a target comprise one or more nucleic acids encoding a site-targeting nuclease and one or more RNAs that cause a Cas nuclease to bind to a target nucleotide sequence. In some aspects, one or more RNAs that cause a Cas nuclease to bind to a target nucleotide sequence comprise a transactivating cRNA (tracrRNA) and a CRISPR RNA (crRNA), or more generally a guide RNA (also referred to as a single guide RNA (sgRNA)), wherein the crRNA and tracrRNA are manipulated into a single RNA molecule. In some aspects, one or more nucleic acids encoding the nuclease encode a site-targeting nuclease including a CRISPR-associated (Cas) nuclease, a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), or a megaTAL.

[0353] Uses of lipid nanoparticles

[0354] In some aspects, the present disclosure provides lipid nanoparticles or a composition containing them for use in a method of targeting the delivery of nucleic acids to target cells of a subject as disclosed herein. In some aspects, the present disclosure provides lipid nanoparticles or a composition containing them for use in a method of targeting the delivery of nucleic acids to immune cells of a subject as disclosed herein. In some aspects, the nucleic acid encodes an immune cell function-enhancing polypeptide, and such nucleic acid is targeted to immune cells by the lipid nanoparticles. In some aspects, the lipid nanoparticles comprise an immune cell targeting group for targeting the delivery of nucleic acids to immune cells.

[0355] In some aspects, the present disclosure provides lipid nanoparticles or compositions containing such nanoparticles for use in a method of targeting nucleic acid delivery to hematopoietic stem cells of a subject as disclosed herein. In some aspects, the nucleic acid of the lipid nanoparticles encodes a polypeptide that functions in gene editing, and such nucleic acid is targeted to hematopoietic stem cells by said lipid nanoparticles. In some aspects, the lipid nanoparticles comprise a hematopoietic stem cell targeting group for targeting nucleic acid delivery to hematopoietic stem cells.

[0356] In some aspects, the present disclosure provides lipid nanoparticles or a composition containing them for use in a method for treating a disease or pathological condition of a subject as disclosed herein. In some aspects, the lipid nanoparticles comprise a nucleic acid encoding an immune cell function-enhancing polypeptide, such as a CAR, and targeted immune cells expressing the CAR treat the disease or pathological condition of the subject. In some aspects, the lipid nanoparticles comprise a nucleic acid providing a component of a gene editing system, and targeted hematopoietic stem cells after gene editing treat the disease or pathological condition of the subject. In some aspects, the composition used in the method is a pharmaceutical composition.

[0357] Kit

[0358] In some aspects, a kit for treating a disorder is provided. In some aspects, the kit comprises: ionizable cationic lipids, auxiliary lipids, structural lipids, PEG lipids, Cargo, lipid-immune cell targeting conjugates, and / or lipid-hematopoietic stem cell targeting conjugates, and instructions for the preparation of lipid nanoparticles and for the treatment of a medical disorder using lipid nanoparticles. In some aspects, the kit comprises a lipid nanoparticle composition comprising lipid nanoparticles comprising ionizable cationic lipids, auxiliary lipids, structural lipids, PEG lipids, Cargo, lipid-immune cell targeting conjugates and / or lipid-hematopoietic stem cell targeting conjugates, and instructions for the treatment of a medical disorder using the lipid nanoparticle composition or lipid nanoparticles.

[0359] Examples

[0360] Example 1: Preparation of lipid nanoparticles

[0361] Lipid nanoparticles (LNPs) encapsulating mRNA cargo were prepared by mixing an aqueous mRNA solution with an ethanolic lipid blend solution (containing ionizable lipids, DSPC, DPG-PEG, and cholesterol in the lipid ratios shown in Table 2) using an inline microfluidic mixing process. The mRNA cargo used for immune cell-targeting LNPs was eGFP mRNA, and the mRNA cargo used for HSC-targeting LNPs was mCherry mRNA. Several lipid nanoparticles were prepared with different amounts of DSPC, e.g., 10 mol%, 12.5 mol%, 15 mol%, 20 mol%, 30 mol%, or 40 mol%.

[0362] mRNA and lipid solutions were mixed using a NanoAssemblr Ignite microfluidic mixer (part number NIN0001) and an NxGen mixing cartridge (part number NIN0002) from Precision Nanosystems Inc. (British Columbia, CA). Briefly, the mRNA and lipid solutions were loaded into separate polypropylene syringes. The mixing cartridge was inserted into the NanoAssemblr Ignite, and the syringe was mounted in the Luer port of the mixing cartridge. Subsequently, the two solutions were mixed using the NanoAssemblr Ignite at a total flow rate of 9 mL / min in a 3:1 v / v ratio of mRNA solution (1.5 mL) to lipid solution (0.5 mL). The resulting suspension was maintained at room temperature for at least 5 minutes before proceeding with ethanol removal and buffer exchange.

[0363] After mixing, ethanol removal and buffer exchange were performed on the resulting LNP suspension using a discontinuous volume filtration process. A centrifugal ultrafiltration apparatus (Amicon Ultra-15, MilliporeSigma, Massachusetts, US) equipped with a 100,000 kDa MWCO regenerated cellulose membrane was sterilized with a 70% ethanol solution and then washed twice with HBS exchange buffer (25 mM pH 7.4 HEPES buffer containing 150 mM NaCl). Subsequently, the LNP suspension (2 mL) was loaded into the apparatus and centrifuged at 500 RCF until the volume was reduced to half volume (1 mL). Then, the suspension was diluted with exchange buffer (1 mL, 25 mM pH 7.4 HEPES buffer) to return the suspension to its original volume. This process of doubling the concentration and doubling the dilution was repeated five additional times for a total of six discontinuous volume filtration steps. Next, the LNP suspension was diluted 10-fold with MBS and exchanged with MBS (25 mM pH 6.5 MES buffer containing 150 mM NaCl) by centrifuging at 500 RCF until the volume was reduced to one-tenth. This 10-fold dilution and 10-fold concentration step using MBS was repeated once more. The residue containing LNP in the MBS was recovered from the centrifugal ultrafiltration apparatus and stored at 4°C until further use.

[0364] Example 2: Characterization of LNP

[0365] Samples of the LNP prepared in Example 1 were characterized to determine the mean hydrodynamic diameter, zeta potential, and mRNA content (total mRNA and dye-accessible mRNA). The hydrodynamic diameter was determined by dynamic light scattering (DLS) using a Zetasizer model ZEN3600 (Malvern Pananalytical, UK). The zeta potential was measured by laser Doppler electrophoresis using a Zetasizer in 5 mM pH 5.5 MES buffer and 5 mM pH 7.4 HEPES buffer. The results for Formulations 1 and 2 LNPs are shown in Table 2.

[0366]

[0367] Example 3: Preparation of a conjugate to enable T cell and hematopoietic stem cell targeting

[0368] VHH, which binds to T cell-specific targets (CD8) and HSC-specific targets (CD117), was conjugated to DSPE-PEG(3.4K)-maleimide and DSPE-PEG(2k)-maleimide, respectively, through covalent coupling between the C-terminal cysteine ​​and maleimide groups of the heavy chain (HC). In a representative reaction, a protein solution in PBS containing 5 mM EDTA was concentrated to 3 to 4 mg / mL using a 10 kDa MWCO regenerated cellulose centrifugation filter. The C-terminal cysteine ​​residue was selectively reduced using 2 to 5 mM TCEP for 1.5 hours at room temperature. The TCEP was removed using a 7K MWCO spin desalting column. The reduced protein was mixed with a mixture of DSPE-PEG-Mal and DSPE-PEG-OMe at a molar ratio of 1:1 for DSPE-PEG-Mal to Fab or VHH and 1:4 for DSPE-PEG-Mal to DSPE-PEG-OMe. The reaction mixture was incubated at 37°C for 2 hours and then quenched with 15 mM cysteine ​​at 37°C for 15 minutes. Subsequently, the resulting DSPE-PEG-Fab or DSPE-PEG-VHH micelles were concentrated using a 50K MWCO regenerated cellulose centrifuge filter and buffered with pH 7.4 HEPES buffered saline. This concentration and buffer exchange process also removes residual cystine and unreacted Fab or VHH. The material was characterized by SDS-PAGE and HPLC. The concentration of Fab or VHH was determined by measuring the absorbance at 280 nm.

[0369] Example 4: Human T cell transfection

[0370] Human CD8+ T cells were isolated from healthy donor PBMCs and cultured with human IL-2 for 24 hours (Day 0). LNPs containing DSPC auxiliary lipids, CAR mRNA, and GFP mRNA at concentrations of 10 mol%, 12.5 mol%, 15 mol%, 20 mol%, 30 mol%, or 40 mol%, respectively, were used for T cell transfection. On Day 1, CD8+ cells were transfected with LNPs at increasing concentrations (0.012 μg / ml, 0.037 μg / ml, 0.11 μg / ml, 0.33 μg / ml, 1 μg / ml, or 3 μg / ml). Transfected cells were washed and stained after 4 hours, and then analyzed immediately (Hour 0) or after 24, 48, and 72 hours to determine the percentage of CAR-positive cells and the average CAR fluorescence intensity. The results for T cells transfected with 0.33 μg / ml LNP containing 10 mol% to 40 mol% DSPC are shown in Fig. 1. T cells transfected with LNP containing 20 mol%, 30 mol%, or 40 mol% DSPC exhibited sustained transfection efficiency, with more than 80% of T cells expressing CAR during a measurement period of 72 hours (Fig. 1a). In contrast, T cells transfected with LNP containing 10 mol% DSPC gradually disappeared over a period of 72 hours (Fig. 1a). Additionally, T cells transfected with LNP containing 20 mol% DSPC exhibited substantially higher mean fluorescence intensity (MFI) than T cells transfected with LNP containing 10 mol%, 30 mol%, or 40 mol% DSPC (Fig. 1b). These results demonstrated the high transfection efficacy and low toxicity of LNP containing 20 mol% DSPC.

[0371] Example 5: Efficacy of target cell death by LNP-treated T cells

[0372] Human T effector cells transfected with 0.037 μg / ml LNP containing 10 mol% to 40 mol% DSPC were incubated with Nalm6 target cells at E:T ratios of 0.01 to 20, and the percentage of Nalm6 target cells killed was determined. Effector T cells transfected with LNP containing 20 mol%, 30 mol%, and 40 mol% DSPC killed more Nalm6 target cells than effector T cells transfected with LNP containing 10 mol% DSPC (Fig. 2a). Among effector T cells, more than 50% of cells transfected with LNP containing 20 mol% DSPC expressed CAR, whereas only 10% of T effector cells transfected with LNP containing 10 mol% DSPC expressed CAR. Approximately 30% and 40% of effector T cells transfected with LNPs containing 30 mol% and 40 mol% DSPC, respectively, expressed CAR (Fig. 2b). Additionally, the mean fluorescence intensity (MFI) of CAR was highest in effector T cells transfected with LNPs containing 20 mol% DSPC compared to T cells transfected with LNPs containing 10 mol%, 30 mol%, or 40 mol% DSPC (Fig. 2c).

[0373] Effector cell function was measured over a period of 16 days. Effector T cells transfected with LNPs containing 10 mol% to 40 mol% DSPC were co-cultured with Nalm6 target cells expressing red fluorescent protein at an E:T ratio of 2:1, and red fluorescence was measured over a period of 16 days. New Nalm6 target cells were added to the co-culture every 2 to 3 days, and LNPs were added to the co-culture on day 8. Only effector T cells transfected with LNPs containing 20 mol% DSPC effectively eliminated Nalm6 target cells over a period of 16 days (Figs. 3a and 3b). In contrast, effector T cells transfected with LNPs containing 10 mol% DSPC reduced the number of Nalm6 targets only slightly (Figs. 3a and 3b). In addition, compared to less than 20% in the group transfected with 10 mol% DSPC LNP, about 55% of the lymphocytes in the group transfected with 20 mol% DSPC LNP were viable CD8+ effector T cells on day 16, which indicates prolonged target engagement, proliferation, and survival in the 20 mol% DSPC LNP group (Fig. 3c).

[0374] Example 6: Efficacy of targeting T cells of different human donors by LNP

[0375] T cells from two different human donors (Donor 10208 and Donor 11771) were transfected with 0.11 μg / ml LNP containing 10 mol%, 12.5 mol%, 15 mol%, and 20 mol% of DSPC auxiliary lipids, and CAR mRNA and GFP mRNA, respectively. The percentage of CAR+ cells and CAR MFI were determined immediately or after 24, 48, 72, and 144 hours. T cells from the two donors transfected with LNP containing 15 mol% or 20 mol% DSPC exhibited approximately 80% CAR+ cells at the 72-hour measurement period, whereas T cells transfected with LNP containing 10 mol% or 12.5 mol% exhibited a lower percentage of CAR+ cells, and the percentage of CAR+ T cells decreased after 48 hours (Figs. 4a and 4c). T cells from two donors transfected with LNPs containing 20 mol% DSPC showed the highest CAR MFI, whereas the CAR MFI was slightly lower in T cells transfected with LNPs containing 15 mol% DSPC and substantially lower in T cells transfected with LNPs containing 10 mol% and 12.5 mol% DSPC (Figs. 4b and 4d).

[0376] In the CAR+ cells of both donors, T cells transfected with LNPs containing 20 mol% DSPC exhibited the highest CAR MFI compared to T cells transfected with LNPs containing 10 mol%, 12.5 mol%, or 15 mol% DSPC (Figs. 4e and 4f).

[0377] These results demonstrated that LNPs containing 20 mol% DSPC auxiliary lipids highly efficiently transfected human T cells from different donors and provided CAR-expressing T cells over a period of 72 hours. In contrast, LNPs containing 10 mol% DSPC exhibited the lowest transfection efficiency and resulted in the loss of transfection at approximately 48 hours. LNPs containing 15 mol% DSPC showed similar transfection efficiency to LNPs containing 20 mol% DSPC, but the overall CAR MFI was lower. The performance of LNPs containing 12.5 mol% DSPC was intermediate between the 10 mol% DSPC LNP and the 15 mol% LNP.

[0378] The binding and expression of transfected CARs to CAR-target proteins were determined by primary staining with recombinant antigens, secondary staining with FITC- or APC-conjugated target antigen antibodies, and flow cytometry. T cells transfected with LNPs containing 20 mol% DSPC exhibited the highest binding to immobilized CAR targets compared to T cells transfected with 15 mol%, 12.5 mol%, or 10 mol% DSPC LNPs (Figs. 5a to 5c).

[0379] Example 7: Transfection of human hematopoietic stem cells

[0380] Humanized NSG™ mice were generated using CD117+ / CD34+ human hematopoietic stem cells (HSCs). HSC-targeted LNPs coated with anti-CD117 Fab(Ab1) were prepared using LNP formulations containing 10 mol% DSPC (Formulation 1) or 20 mol% DSPC (Formulation 2) (see Table 2 for complete LNP composition).

[0381] Humanized NSG™ mice were treated by intravenous injection of 1 mg / kg of LNP encapsulating mCherry mRNA coated with anti-CD117 Fab, and transfection efficiency was measured in NSG™ bone marrow.

[0382] Transfection efficiencies ranging from 20% to approximately 80% were measured in vivo using two different LNP formulations (Fig. 6a). Additionally, the median fluorescence intensity of HSCs transfected with formulation 2 was measured to increase by more than twofold in vivo compared to HSCs transfected with formulation 1 (not shown). Off-target signals measured in the liver and lungs were lower in NSG™ mice treated with 20 mol% DSPC LNP compared to 10 mol% DSPC (Fig. 6b).

[0383] Overall, these results demonstrated the enhanced efficacy of the 20 mol% DSPC-containing LNP described herein for in vivo transfection of human HSCs.

[0384] CD117+ / CD34+ human hematopoietic stem cells (HSCs) were cultured in vitro and transfected with various doses of anti-CD117 Fab(Ab1) coated HSC-targeting LNP using LNP formulations containing 10 mol% DSPC (Formulation 1) or 20 mol% DSPC (Formulation 2) (see Table 2 for complete LNP composition).

[0385] When LNP formulation 1 was used at a minimum dose of about 0.01 micrograms / mL, the transfection efficiency was 5%, whereas when LNP formulation 2 was used at the same dose, the transfection efficiency was 50% (Fig. 7a). As shown in Fig. 7b, when LNP formulation 2 at 1 microgram / mL was used at the same dose as LNP formulation 1, the MFI increased by about 4 times.

[0386] Overall, these results demonstrated the enhanced efficacy of the 20 mol% DSPC-containing LNP described herein for the in vitro transfection of human HSCs.

[0387] In the present application, where it is stated that a component or component is included in and / or selected from a list of listed components or components, it should be understood that the component or component may be any one of the listed components or components, or that the component or component may be selected from a group consisting of two or more of the listed components or components.

[0388] Furthermore, it should be understood that the components and / or features of the composition or method described herein may be combined in various ways without departing from the spirit and scope of the invention, whether explicitly or implicitly described herein. For example, where specific compounds are mentioned, unless otherwise understood from the context, said compounds may be used in various aspects of the composition of the invention and / or in the method of the invention. In other words, although aspects in this application are described and illustrated in a manner that allows for a clear and concise application to be drawn and drawn, it is intended and understood that the aspects may be combined or separated in various ways without departing from the teachings and the invention. For example, it should be understood that all features described and illustrated herein may be applicable to all aspects of the invention described and illustrated herein.

[0389] embodiments

[0390] 1. A lipid nanoparticle for targeted delivery of nucleic acid into a target cell, wherein the lipid nanoparticle comprises a cell targeting group and a lipid blend comprising an ionizable lipid, a structural lipid, an auxiliary lipid, and a PEG lipid, wherein the auxiliary lipid is present in the lipid blend in a range of about 16 mol% to about 40 mol%.

[0391] 2. In Embodiment 1, the lipid nanoparticle, wherein the ionizable lipid is a compound of Formula I or a salt thereof:

[0392] [Chemical Formula I]

[0393]

[0394] (Here,

[0395] R 1 , R 2 , and R 3 Each is independently combined or C 1-3 It is an alkylene;

[0396] R 1A , R 2A , and R 3A are each independently combined or C 1-10 It is an alkylene;

[0397] R 1A1 , R 1A2 , R 1A3 , R 2A1 , R 2A2 , R 2A3 , R 3A1 , R 3A2 , and R 3A3 H and C are independently 1-20 Alkyl, C 1-20 Alkenyl, -(CH2) 0-10 C(O)OR a1 , or -(CH2) 0-10 OC(O)R a2 And;

[0398] R a1 and R a2 C each independently 1-20 alkyl or C 1-20It is alkenyl; R 3B Is

[0399]

[0400] And,

[0401] R 3B1 C 1-6 It is an alkylene;

[0402] R 3B2 and R 3B3 Each independently H or C 1-6 It is an alkyl).

[0403] 3. In Embodiment 2, the ionizable lipid is

[0404] Phosphorus, lipid nanoparticles.

[0405] 4. A lipid nanoparticle comprising, in any one of embodiments 1 to 3, additionally a cargo.

[0406] 5. In any one of embodiments 1 to 4, the auxiliary lipid is a lipid nanoparticle selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and sphingomyelin.

[0407] 6. A lipid nanoparticle, wherein in any one of embodiments 1 to 5, the auxiliary lipid is DSPC.

[0408] 7. In any one of embodiments 1 to 6, the lipid nanoparticles, wherein the auxiliary lipid is present in the lipid blend in a range of about 16 mol% to about 30 mol%.

[0409] 8. In embodiment 7, the auxiliary lipid is a lipid nanoparticle present in the lipid blend in a range of about 16 mol% to about 25 mol%.

[0410] 9. In embodiment 8, the auxiliary lipid is a lipid nanoparticle present in the lipid blend at about 20 mol%.

[0411] 10. In any one of embodiments 1 to 9, the lipid nanoparticles wherein the structural lipid is selected from the group consisting of cholesterol, pecosterol, β-sitosterol, ergosterol, campesterol, stigmasterol, stigmasterol, and brassicasterol.

[0412] 11. In any one of embodiments 1 to 10, the PEG lipid is a lipid nanoparticle selected from the group consisting of distearoylglycerol-PEG (DSG-PEG), distearoyl-phosphatidylethanolamine-PEG (DSPE-PEG), dimyristoyl-phosphatidylethanolamine-PEG (DMPE-PEG), distearoyl-glycero-phosphoglycerol-PEG (DSPG-PEG), dimyristoyl-glycerol-PEG (DMG-PEG), dipalmitoyl-phosphatidylethanolamine-PEG (DPPE-PEG), dipalmitoyl-glycerol-PEG (DPG-PEG), and ceramide-PEG.

[0413] 12. In any one of embodiments 1 to 11, the lipid nanoparticles, wherein the ionizable lipid is present in the lipid blend in a range of about 30 mol% to about 70 mol%.

[0414] 13. In any one of embodiments 1 to 12, the lipid nanoparticles, wherein the ionizable lipid is present in the lipid blend in a range of about 40 mol% to about 60 mol%.

[0415] 14. In any one of embodiments 1 to 13, the lipid nanoparticles, wherein the ionizable lipid is present in the lipid blend in a range of about 48 mol% to about 50 mol%.

[0416] 15. In any one of embodiments 1 to 14, the lipid nanoparticles, wherein the structural lipid is present in the lipid blend in a range of about 20 mol% to about 50 mol%.

[0417] 16. In any one of embodiments 1 to 15, the lipid nanoparticles, wherein the structural lipid is present in the lipid blend in a range of about 30 mol% to about 40 mol%.

[0418] 17. A lipid nanoparticle in any one of embodiments 1 to 16, wherein the structural lipid is cholesterol.

[0419] 18. Lipid nanoparticles in the lipid blend of embodiment 17, wherein cholesterol is present in the lipid blend in a range of about 25 mol% to about 40 mol%.

[0420] 19. In any one of embodiments 1 to 18, the lipid nanoparticles, wherein the PEG lipid is present in the lipid blend in a range of about 1 mol% to about 4 mol%.

[0421] 20. A lipid nanoparticle in any one of embodiments 1 to 19, wherein the PEG lipid is DPG-PEG or DSPE-PEG.

[0422] 21. Lipid nanoparticles in Example 20, wherein the PEG in DPG-PEG has a molecular weight of about 2000 daltons (DPG-PEG2K) and the PEG in DSPE-PEG has a molecular weight of about 2000 daltons (DSPE-PEG2K) or about 3400 daltons (DSPE-PEG3.4K).

[0423] 22. In embodiment 21, DPG-PEG2K, DSPE-PEG2K, or DSPE-PEG3.4K are lipid nanoparticles present in the lipid blend in a range of about 1 mol% to about 2 mol%.

[0424] 23. Lipid nanoparticles in any one of embodiments 1 to 22, wherein Lipid 15 is present in the lipid blend at about 49.25 mol%, cholesterol is present at about 29.25 mol%, DSPC is present at about 20 mol%, and DPG-PEG2K is present at about 1.5 mol%.

[0425] 24. In any one of embodiments 1 to 23, the lipid nanoparticles are lipid nanoparticles having an average diameter of about 60 nm to about 100 nm.

[0426] 25. In any one of embodiments 1 to 24, the lipid nanoparticles are lipid nanoparticles having an average diameter of about 80 nm.

[0427] 26. In any one of embodiments 1 to 25, the lipid nanoparticles have a polydispersity index (PDI) of about 0.05 to about 1.

[0428] 27. In embodiment 26, the lipid nanoparticles are lipid nanoparticles having a PDI of about 0.09.

[0429] 28. In any one of embodiments 1 to 27, the lipid nanoparticles have a zeta potential (ZP) of about -30 mV to about +5 mV.

[0430] 29. In embodiment 28, the lipid nanoparticles are lipid nanoparticles having a ZP of about -1.4 mV.

[0431] 30. In any one of embodiments 4 to 29, the cargo is a lipid nanoparticle comprising one or more nucleic acids.

[0432] 31. A lipid nanoparticle in which, in embodiment 30, one or more nucleic acids are DNA.

[0433] 32. A lipid nanoparticle in which, in embodiment 30, one or more nucleic acids are RNA.

[0434] 33. In embodiment 32, the lipid nanoparticle comprises RNA encoding guide RNA and RNA encoding a Cas enzyme.

[0435] 34. In any one of embodiments 30 to 32, the lipid nanoparticles wherein one or more nucleic acids encode a chimeric antigen receptor (CAR).

[0436] 35. A lipid nanoparticle in any one of embodiments 1 to 34, wherein the cell targeting agent is coupled to the lipid of the lipid nanoparticle to form a lipid-cell targeting agent conjugate.

[0437] 36. In embodiment 35, the cell targeting group is a lipid nanoparticle coupled to PEG-lipid.

[0438] 37. In embodiment 36, the cell targeting group is a lipid nanoparticle coupled to DPG-PEG2K, DSPE-PEG2K, or DSPE-PEG3.4K.

[0439] 38. In any one of embodiments 35 to 37, the cell targeting group comprises a lipid nanoparticle comprising an antibody or a fragment thereof.

[0440] 39. In embodiment 38, the cell targeting group comprises a lipid nanoparticle containing an antibody.

[0441] 40. In embodiment 38, the cell targeting agent is a lipid nanoparticle comprising a Fab fragment.

[0442] 41. In embodiment 38, the cell targeting agent is a lipid nanoparticle comprising a single variable domain.

[0443] 42. In any one of embodiments 35 to 41, the cell targeting group is a lipid nanoparticle that binds to a molecule on an immune cell.

[0444] 43. In embodiment 42, the molecule on the immune cell is a lipid nanoparticle selected from the group consisting of CD3, CD4, CD7, and CD8.

[0445] 44. In any one of embodiments 35 to 41, the cell targeting group is a lipid nanoparticle that binds to a molecule on a hematopoietic stem cell.

[0446] 45. In embodiment 44, the molecule on the hematopoietic stem cell is a lipid nanoparticle selected from the group consisting of CD34, CD105, and CD117.

[0447] 46. ​​In any one of embodiments 35 to 45, the lipid-cell targeting conjugate is present in the lipid nanoparticle in a range of about 0.001 mol% to about 0.5 mol%.

[0448] 47. A pharmaceutical composition comprising any one of the lipid nanoparticles of embodiments 1 to 46, and one or more pharmaceutically acceptable carriers or excipients.

[0449] 48. A method for delivering nucleic acid to a cell of a subject, wherein the method comprises administering a lipid nanoparticle of any one of embodiments 1 to 46 or a pharmaceutical composition of embodiment 47 to a subject.

[0450] 49. Method according to embodiment 48, wherein the cell is an immune cell.

[0451] 50. Method according to embodiment 48, wherein the cell is a hematopoietic stem cell.

[0452] 51. Use of any one of the lipid nanoparticles of Examples 1 to 46 or the pharmaceutical composition of Example 47 in the manufacture of a drug for delivering nucleic acids to cells.

[0453] 52. In embodiment 51, the cell is an immune cell.

[0454] 53. In embodiment 51, the cell is a hematopoietic stem cell.

[0455] 54. A lipid nanoparticle of any one of Examples 1 to 46 or a pharmaceutical composition of Example 47 for use in delivering nucleic acids to cells.

[0456] 55. In embodiment 54, the cell is a lipid nanoparticle that is an immune cell.

[0457] 56. In embodiment 54, the lipid nanoparticle, wherein the cell is a hematopoietic stem cell.

[0458] 57. A method for treating a disease in a subject requiring treatment, wherein the method comprises administering a lipid nanoparticle of any one of embodiments 1 to 46 or a pharmaceutical composition of embodiment 47 to the subject.

[0459] 58. A method for treating a disease of a subject, wherein the method comprises administering a lipid nanoparticle of any one of Examples 1 to 46 or a pharmaceutical composition of Example 47 to immune cells of the subject requiring the treatment.

[0460] 59. A method according to embodiment 58, wherein the administration is to a plurality of immune cells.

[0461] 60. A method according to embodiment 59, wherein a protein encoded by one or more nucleic acids disposed in the lipid nanoparticles is detected in more than 60% (or even 80%) of immune cells at 72 hours after administration of the lipid nanoparticles.

[0462] 61. A method according to embodiment 60, wherein the protein is detected in more immune cells of a subject at 72 hours after administration of the lipid nanoparticles compared to another subject administered the lipid nanoparticles containing an auxiliary lipid present at 10 mol% in the lipid blend.

[0463] 62. A method according to embodiment 59, wherein a protein encoded by one or more nucleic acids disposed on the lipid nanoparticles increases the effector function of the immune cell or a plurality of immune cells compared to an immune cell or a plurality of immune cells to which the lipid nanoparticles have not been administered.

[0464] 63. A method for treating a disease of a subject, wherein the method comprises administering a lipid nanoparticle of any one of embodiments 1 to 41 and 44 to 46 or a pharmaceutical composition of embodiment 47 to hematopoietic stem cells of a subject requiring such a drug.

[0465] 64. A method according to embodiment 63, wherein the lipid nanoparticles are administered to a plurality of hematopoietic stem cells of a subject.

[0466] 65. A method according to embodiment 63 or 64, wherein a protein encoded by one or more nucleic acids disposed on the lipid nanoparticles is detected in at least 80% of the hematopoietic stem cells of a plurality of hematopoietic stem cells of a subject.

[0467] 66. A method according to embodiment 65, wherein the protein is detected in about 20% of hematopoietic stem cells administered with lipid nanoparticles containing an auxiliary lipid present in 10 mol% of the lipid blend.

[0468] 67. A lipid nanoparticle of any one of embodiments 1 to 46 or a pharmaceutical composition of embodiment 47 for use in treating a disease of a subject requiring treatment for the disease.

[0469] 68. A lipid nanoparticle of any one of embodiments 1 to 43 and 46 or a pharmaceutical composition of embodiment 47 for use in the treatment of immune cell-related diseases in subjects requiring treatment for immune cell-related diseases.

[0470] 69. A lipid nanoparticle of any one of embodiments 1 to 41 and 44 to 46 or a pharmaceutical composition of embodiment 47 for use in the treatment of a hematopoietic stem cell-related disease in a subject requiring treatment for a hematopoietic stem cell-related disease.

[0471] 70. In embodiment 69, the lipid nanoparticle, wherein the hematopoietic stem cell-related disease is sickle cell disease.

Claims

Claim 1 A lipid nanoparticle for targeted delivery of nucleic acid into a target cell, wherein the lipid nanoparticle comprises a cell targeting group and a lipid blend comprising an ionizable lipid, a structural lipid, an auxiliary lipid, and a PEG lipid, wherein the auxiliary lipid is present in the lipid blend in a range of about 16 mol% to about 40 mol%. Claim 2 In claim 1, the lipid nanoparticles, wherein the ionizable lipid is a compound of Formula I or a salt thereof: [Formula I] (here, R 1 , R 2 , and R 3 Each is independently combined or C 1-3 It is an alkylene and;R 1A , R 2A , and R 3A are each independently combined or C 1-10 It is an alkylene and;R 1A1 , R 1A2 , R 1A3 , R 2A1 , R 2A2 , R 2A3 , R 3A1 , R 3A2 , and R 3A3 H and C are independently 1-20 Alkyl, C 1-20 Alkenyl, -(CH2) 0-10 C(O)OR a1 , or -(CH2) 0-10 OC(O)R a2 Igo;R a1 and R a2 C each independently 1-20 alkyl or C 1-20 It is alkenyl; R 3B Is and, R 3B1 C 1-6 It is an alkylene and;R 3B2 and R 3B3 Each independently H or C 1-6 It is an alkyl). Claim 3 In paragraph 2, the ionizable lipid is Phosphorus, lipid nanoparticles. Claim 4 A lipid nanoparticle comprising additionally a cargo in any one of paragraphs 1 to 3. Claim 5 A lipid nanoparticle according to any one of claims 1 to 4, wherein the auxiliary lipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and sphingomyelin. Claim 6 In any one of claims 1 to 5, the lipid nanoparticle, wherein the auxiliary lipid is DSPC. Claim 7 In any one of claims 1 to 6, the lipid nanoparticles are present in the lipid blend in a range of about 16 mol% to about 30 mol%. Claim 8 In claim 7, the auxiliary lipid is a lipid nanoparticle present in the lipid blend in a range of about 16 mol% to about 25 mol%. Claim 9 In claim 8, the auxiliary lipid is a lipid nanoparticle present in the lipid blend at about 20 mol%. Claim 10 Lipid nanoparticles according to any one of claims 1 to 9, wherein the structural lipid is selected from the group consisting of cholesterol, pecosterol, β-sitosterol, ergosterol, campesterol, stigmasterol, stigmasterol, and brassicasterol. Claim 11 A lipid nanoparticle according to any one of claims 1 to 10, wherein the PEG lipid is selected from the group consisting of distearoylglycerol-PEG (DSG-PEG), distearoyl-phosphatidylethanolamine-PEG (DSPE-PEG), dimyristoyl-phosphatidylethanolamine-PEG (DMPE-PEG), distearoyl-glycero-phosphoglycerol-PEG (DSPG-PEG), dimyristoyl-glycerol-PEG (DMG-PEG), dipalmitoyl-phosphatidylethanolamine-PEG (DPPE-PEG), dipalmitoyl-glycerol-PEG (DPG-PEG), and ceramide-PEG. Claim 12 In any one of claims 1 to 11, the lipid nanoparticles, wherein the ionizable lipid is present in the lipid blend in a range of about 30 mol% to about 70 mol%. Claim 13 In any one of claims 1 to 12, the lipid nanoparticles, wherein the ionizable lipid is present in the lipid blend in a range of about 40 mol% to about 60 mol%. Claim 14 A lipid nanoparticle according to any one of claims 1 to 13, wherein the structural lipid is cholesterol. Claim 15 In claim 14, the lipid nanoparticles, wherein cholesterol is present in the lipid blend in a range of about 25 mol% to about 40 mol%. Claim 16 Lipid nanoparticles according to any one of claims 1 to 15, wherein the PEG lipid is present in the lipid blend in a range of about 1 mol% to about 4 mol%. Claim 17 A lipid nanoparticle according to any one of claims 1 to 16, wherein the PEG lipid is DPG-PEG or DSPE-PEG. Claim 18 Lipid nanoparticles according to claim 17, wherein the PEG in DPG-PEG has a molecular weight of about 2000 daltons (DPG-PEG2K) and the PEG in DSPE-PEG has a molecular weight of about 2000 daltons (DSPE-PEG2K) or about 3400 daltons (DSPE-PEG3.4K). Claim 19 Lipid nanoparticles according to any one of claims 1 to 18, wherein Lipid 15 is present in the lipid blend at about 49.25 mol%, cholesterol is present at about 29.25 mol%, DSPC is present at about 20 mol%, and DPG-PEG2K is present at about 1.5 mol%. Claim 20 In any one of claims 1 to 19, the lipid nanoparticles are lipid nanoparticles having an average diameter of about 60 nm to about 100 nm. Claim 21 In any one of claims 1 to 20, the lipid nanoparticles are lipid nanoparticles having a polydispersity index (PDI) of about 0.05 to about 1. Claim 22 In any one of claims 1 to 21, the lipid nanoparticles are lipid nanoparticles having a zeta potential (ZP) of about -30 mV to about +5 mV. Claim 23 In any one of paragraphs 4 to 22, the said cargo is a lipid nanoparticle comprising one or more nucleic acids. Claim 24 In paragraph 23, lipid nanoparticles in which one or more of the nucleic acids are RNA. Claim 25 A lipid nanoparticle according to any one of claims 1 to 24, wherein the cell targeting agent is coupled to the lipid of the lipid nanoparticle to form a lipid-cell targeting agent conjugate. Claim 26 In paragraph 25, the cell targeting agent is a lipid nanoparticle coupled to the PEG-lipid. Claim 27 In paragraph 25 or 26, the cell targeting device is a lipid nanoparticle comprising an antibody or a fragment thereof. Claim 28 In any one of claims 25 to 27, the cell targeting unit is a lipid nanoparticle that binds to a molecule on an immune cell. Claim 29 In claim 28, the molecule on the immune cell is a lipid nanoparticle selected from the group consisting of CD3, CD4, CD7, and CD8. Claim 30 In any one of claims 25 to 27, the cell targeting agent is a lipid nanoparticle that binds to a molecule on a hematopoietic stem cell. Claim 31 In claim 30, the molecule on the hematopoietic stem cell is a lipid nanoparticle selected from the group consisting of CD34, CD105, and CD117. Claim 32 A lipid nanoparticle according to any one of claims 25 to 31, wherein the lipid-cell targeting conjugate is present in the lipid nanoparticle in a range of about 0.001 mol% to about 0.5 mol%. Claim 33 A pharmaceutical composition comprising lipid nanoparticles according to any one of claims 1 to 32, and one or more pharmaceutically acceptable carriers or excipients. Claim 34 A method for delivering nucleic acids to cells of a target, wherein the method comprises administering lipid nanoparticles of any one of claims 1 to 32 or a pharmaceutical composition of claim 33 to the target. Claim 35 In paragraph 34, the above cell is an immune cell, method. Claim 36 In paragraph 34, the cell is a hematopoietic stem cell. Claim 37 A method for treating a disease in a subject requiring treatment for the disease, wherein the method comprises administering to the subject lipid nanoparticles of any one of claims 1 to 32 or the pharmaceutical composition of claim 33.